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Approximately 2.5% of all hospitalisations in people with liver cirrhosis are for spontaneous bacterial peritonitis. Spontaneous bacterial
 
peritonitis is associated with significant short­term mortality; therefore, it is important to prevent spontaneous bacterial peritonitis in
 
people at high risk of developing it. Antibiotic prophylaxis forms the mainstay preventive method, but this has to be balanced against
 
the development of drug­resistant spontaneous bacterial peritonitis, which is difficult to treat, and other adverse events. Several different
 




To compare the benefits and harms of different prophylactic antibiotic treatments for prevention of spontaneous bacterial peritonitis
 
in people with liver cirrhosis using a network meta­analysis and to generate rankings of the different prophylactic antibiotic treatments
 




We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials
 






We included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis undergoing prophylactic
 
treatment to prevent spontaneous bacterial peritonitis. We excluded randomised clinical trials in which participants had previously
 
undergone liver transplantation, or were receiving antibiotics for treatment of spontaneous bacterial peritonitis or other purposes.
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Data collection and analysis
 
We performed a network meta­analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio
 
(HR) with 95% credible intervals (CrI) based on an available­case analysis, according to National Institute of Health and Care Excellence
 




We included 29 randomised clinical trials (3896 participants; nine antibiotic regimens (ciprofloxacin, neomycin, norfloxacin, norfloxacin
 
plus neomycin, norfloxacin plus rifaximin, rifaximin, rufloxacin, sparfloxacin, sulfamethoxazole plus trimethoprim), and 'no active
 
intervention' in the review. Twenty­three trials (2587 participants) were included in one or more outcomes in the review. The trials that
 
provided the information included people with cirrhosis due to varied aetiologies, with or without other features of decompensation,
 
having ascites with low protein or previous history of spontaneous bacterial peritonitis. The follow­up in the trials ranged from 1 to 12
 
months. Many of the trials were at high risk of bias, and the overall certainty of evidence was low or very low. Overall, approximately 10%
 
of trial participants developed spontaneous bacterial peritonitis and 15% of trial participants died.
 
There was no evidence of differences between any of the antibiotics and no intervention in terms of mortality (very low certainty) or number
 
of serious adverse events (very low certainty). However, because of the wide CrIs, clinically important differences in these outcomes cannot
 
be ruled out. None of the trials reported health­related quality of life or the proportion of people with serious adverse events.
 
There was no evidence of differences between any of the antibiotics and no intervention in terms of proportion of people with 'any adverse
 
events' (very low certainty), liver transplantation (very low certainty), or the proportion of people who developed spontaneous bacterial
 
peritonitis (very low certainty). The number of 'any' adverse events per participant was fewer with norfloxacin (rate ratio 0.74, 95% CrI
 
0.59 to 0.94; 4 trials, 546 participants; low certainty) and sulfamethoxazole plus trimethoprim (rate ratio 0.19, 95% CrI 0.02 to 0.81; 1 trial,
 
60 participants; low certainty) versus no active intervention. There was no evidence of differences between the other antibiotics and no
 
intervention in the number of 'any' adverse events per participant (very low certainty). There were fewer other decompensation events
 
with rifaximin versus no active intervention (rate ratio 0.61, 65% CrI 0.46 to 0.80; 3 trials, 575 participants; low certainty) and norfloxacin
 
plus neomycin (rate ratio 0.06, 95% CrI 0.00 to 0.33; 1 trial, 22 participants; low certainty). There was no evidence of differences between
 
the other antibiotics and no intervention in the number of decompensations events per participant (very low certainty). None of the trials
 
reported health­related quality of life or development of symptomatic spontaneous bacterial peritonitis.
 
One would expect some correlation between the above outcomes, with interventions demonstrating effectiveness across several
 
outcomes. This was not the case. The possible reasons for this include sparse data and selective reporting bias, which makes the results
 
unreliable. Therefore, one cannot draw any conclusions from these inconsistent differences based on sparse data.
 




Funding: the source of funding for five trials were organisations who would benefit from the results of the study; six trials received no
 




Based on very low­certainty evidence, there is considerable uncertainty about whether antibiotic prophylaxis is beneficial, and if beneficial,
 




Future randomised clinical trials should be adequately powered, employ blinding, avoid postrandomisation dropouts (or perform
 






Use of antibiotics to prevent spontaneous bacterial peritonitis in people with advanced liver disease
 
What was the aim of this Cochrane Review?
 
People with advanced liver disease (liver cirrhosis, or late­stage scarring of the liver with complications) are at risk of developing an
 
abnormal build­up of fluid in the tummy, called ascites. This fluid may get infected with bacteria, without one knowing the cause. This is
 
called 'spontaneous bacterial peritonitis'. It is important to prevent spontaneous bacterial peritonitis in people at high risk of developing
 
it, because it is associated with a significant risk of death. Antibiotics are often used in people with advanced liver disease and ascites as
 




We aimed to determine the best available antibiotic treatment (if any) for the prevention of spontaneous bacterial peritonitis in people
 
with advanced liver disease. We collected and analysed all relevant research studies and found 29 randomised clinical trials (participants
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are randomly assigned to one of two treatment groups). During analysis of data, we used standard Cochrane techniques, allowing direct
 
comparison of only two treatments at a time. We also used advanced techniques, allowing indirect comparisons of more than two
 
treatments simultaneously (usually referred as 'network meta­analysis'). The aim was to gather reliable direct and indirect evidence.
 






Only two small studies were conducted without flaws, and because of the very high uncertainty in the obtained analysis results, the authors
 
could not say whether antibiotics work and, if they work, which one to use. Out of 1564 participants, 10% of people with cirrhosis and
 
ascites developed spontaneous bacterial peritonitis, and out of 2169 participants, about 15% died within 12 months.
 
Funding source was unclear in 18 studies. Drug companies funded five studies. There were no concerns regarding the source of funding
 
for the remaining six studies.
 
What did the review study?
 
We studied adults with advanced liver disease due to various causes, and who were undergoing preventive treatment to avoid developing
 
spontaneous bacterial peritonitis. Participants received different antibiotics or no antibiotics. We excluded studies in people who had
 
previously undergone liver transplantation, and where people received antibiotics for the treatment of spontaneous bacterial peritonitis
 
or for any other reason. The average age of participants, when reported, ranged from 42 to 63 years. The administered antibiotic types
 
were quinolones, rifamycins, sulfonamides, and aminoglycosides. The authors wanted to gather and analyse data on death, quality of
 
life, serious and non­serious side effects, time to liver transplantation, time to development of spontaneous bacterial peritonitis, time to
 
development of other complications of advanced liver disease, and length of hospital stay.
 
What were the main results of the review?
 
The 29 studies included a small number of participants (3896 participants). Study data were sparse. Twenty­three studies with 2587
 
participants provided data for analyses. The follow­up in the trials ranged from 1 to 12 months. The review shows that:
 
­ of the 10 different antibiotics compared in the trials, norfloxacin and rifaximin were most commonly used;
 
­ 15 of every 100 people died within 12 months, and 10 of every 100 people developed spontaneous bacterial peritonitis;
 
­ giving preventive antibiotics may make no difference to the percentage of deaths or people with serious complications; however,
 
potentially important differences cannot be ruled out;
 
­ none of the trials reported quality of life or symptomatic development of spontaneous bacterial peritonitis;
 
­ there was evidence showing that the percentage of people who developed spontaneous bacterial peritonitis as per laboratory criteria
 
may be reduced with sulfonamides compared with no use of antibiotics (difficult to estimate how much reduction);
 
­ there was evidence of differences in other outcomes such as any complications, liver transplantation, and other signs of liver failure,
 




­ future well­designed trials are needed.
 
Quality of the evidence
 
We cannot draw any conclusions from these trials due to the sparse data.
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Summary of findings for the main comparison. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis
 












































































































































































Network geometry plots: Figure 1
 










No active intervention Reference — — — 
Rifaximin 
(3 RCTs, 479 participants) 
HR 0.57 
(0.33 to 1.00) 
Network estimate 
184 per 1000 105 per 1000 
(61 to 184) 
79 fewer per 1000 
(123 fewer to 0 fewer) 
Very lowa,b,c 
Norfloxacin 
(4 RCTs, 546 participants) 
HR 0.74 
(0.49 to 1.09) 
Network estimate 
184 per 1000 136 per 1000 
(90 to 201) 
48 fewer per 1000 
(94 fewer to 17 more) 
Very lowa,b,c 
Ciprofloxacin 
(3 RCTs, 255 participants) 
HR 0.61 
(0.31 to 1.16) 
Network estimate 
184 per 1000 113 per 1000 
(57 to 213) 
71 fewer per 1000 




(1 RCT, 60 participants) 
HR 0.47 
(0.20 to 1.00) 
Network estimate 
184 per 1000 85 per 1000 
(38 to 184) 
98 fewer per 1000 






























                   
 
           
     
       
 
     
                       
                         




       
     
       
 
                     
 
             
     
       
 
           
     
       
 
             












































































































(no direct RCT) 
HR 0.40 
(0.12 to 1.17) 
Network estimate 
184 per 1000 73 per 1000 
(22 to 215) 
111 fewer per 1000 
(161 fewer to 32 more) 
Very lowa,b,c 
Rufloxacin 
(no direct RCT) 
HR 1.45 
(0.27 to 8.21) 
Network estimate 
184 per 1000 265 per 1000 
(50 to 1000) 
82 more per 1000 
(133 fewer to 816 more) 
Very lowa,b,c 
Health­related quality of life 
None of the trials reported this outcome.
 
Serious adverse events (proportion of participants with one or more serious adverse event)
 
None of the trials with no active intervention as control group reported this outcome.
 
Serious adverse events (number of serious events per participant) 
Total studies: 2 
Total participants: 353 
No active intervention Reference — — — 
Rifaximin 
(2 RCTs, 353 participants) 
Rate ratio 1.66 
(0.98 to 2.90) 
Direct estimate 
132 per 1000 219 per 1000 
(129 to 383) 
87 more per 1000 Very lowa,b,c 
(3 fewer to 251 more) 
Any adverse events (proportion of participants with one or more adverse event) 
Total studies: 3 
Total participants: 631 
No active intervention Reference — — — 
Rifaximin 
(1 RCT, 299 participants) 
OR 1.01 
(0.00 to 853.21) 
Network estimate 
799 per 1000 800 per 1000 
(5 to 1000) 
1 more per 1000 Very lowa,b,c 
(201 fewer to 201 more) 
Norfloxacin 
(no direct RCT) 
OR 11.85 
(0.01 to 263,023.85) 
Network estimate 
799 per 1000 979 per 1000 
(26 to 1000) 
180 more per 1000 Very lowa,b,c 
(201 fewer to 201 more) 
Any adverse events (number of events per participant)
 

































































































       
     




               
     
   




               
 
                     
 
                   
 
   
       
     
       
 
                   










































































































































































No active intervention Reference — — — 
Rifaximin 
(3 RCTs, 418 participants) 
Rate ratio 1.15 
(0.98 to 1.34) 
Direct estimate 
531 per 1000 609 per 1000 
(522 to 710) 
78 more per 1000 
(9 fewer to 169 more) 
Very lowa,b,c 
Norfloxacin Rate ratio 0.74 531 per 1000 393 per 1000 138 fewer per 1000 Lowa,b 
(4 RCTs, 546 participants) (0.59 to 0.94) (312 to 498) (219 fewer to 33 fewer) 
Direct estimate 
Ciprofloxacin 
(3 RCT; 255 participants) 
Rate ratio 0.72 
(0.49 to 1.05) 
Direct estimate 
531 per 1000 384 per 1000 
(261 to 555) 
152 fewer per 1000 
(270 fewer to 24 more) 
Very lowa,b,c 
Sulfamethoxazole + trimetho­ Rate ratio 0.19 531 per 1000 102 per 1000 138 fewer per 1000 Lowa,b 
prim (0.02 to 0.81) (13 to 431) (219 fewer to 33 fewer) 




No active intervention Reference — — — 
Norfloxacin 
(1 RCT, 68 participants) 
HR 0.93 
(0.31 to 3.44) 
Network estimate 
182 per 1000 168 per 1000 
(56 to 625) 
14 fewer per 1000 
(126 fewer to 443 more) 
Very lowa,b,c 
Ciprofloxacin 
(no direct RCT) 
HR 0.62 
(0.12 to 3.31) 
Network estimate 
182 per 1000 113 per 1000 
(22 to 602) 
69 fewer per 1000 





(0.62 to 11.91) 
182 per 1000 477 per 1000 
(114 to 1000) 
295 more per 1000 
(68 fewer to 818 more) 
Very lowa,b,c 
(no direct RCT) Network estimate 









































             
     
       
 
                     
 
                     
 
     
         





               
   
   




               
     
   
               
 
                                             












































































































(2 RCTs, 106 participants) 
HR 7.80 
(0.13 to 4647.11) 
Direct estimate 
140 per 1000 1000 per 1000 
(19 to 1000) 
860 more per 1000 
(121 fewer to 860 more) 
Very lowa,b,c 
Norfloxacin 
(3 RCTs, 255 participants) 
HR 0.16 
(0.00 to 1.56) 
Direct estimate 
140 per 1000 23 per 1000 
(0 to 219) 
117 fewer per 1000 
(140 fewer to 79 more) 
Very lowa,b,c 
Ciprofloxacin 
(3 RCTs, 255 participants) 
HR 0.56 
(0.02 to 60.64) 
Direct estimate 
140 per 1000 78 per 1000 
(2 to 1000) 
62 fewer per 1000 




(1 RCT, 60 participants) 
HR not estimable 
Direct estimate 
140 per 1000 Not estimable Not estimable Very lowa,b,c 
Number of decompensation episodes (per participant) 
Total studies: 8 
Total participants: 1275 
No active intervention Reference — — — 
Norfloxacin + neomycin 
(1 RCT, 22 participants) 
Rate ratio 0.06 
(0.00 to 0.33) 
Network estimate 
459 per 1000 25 per 1000 
(1 to 152) 
434 fewer per 1000 
(458 fewer to 307 fewer) 
Lowa,b 
Norfloxacin + rifaximin 
(no direct RCT) 
Rate ratio 0.33 
(0.04 to 1.40) 
Network estimate 
459 per 1000 151 per 1000 
(19 to 643) 
308 fewer per 1000 
(440 fewer to 184 more) 
Very lowa,b,c 
Rifaximin 
(3 RCTs, 575 participants) 
Rate ratio 0.61 
(0.46 to 0.80) 
Network estimate 
459 per 1000 280 per 1000 
(209 to 365) 
179 fewer per 1000 
(250 fewer to 94 fewer) 
Lowa,b 
Norfloxacin 
(3 RCTs, 439 participants) 
Rate ratio 0.81 
(0.58 to 1.12) 
Network estimate 
459 per 1000 372 per 1000 
(268 to 515) 
87 fewer per 1000 
(192 fewer to 56 more) 
Very lowa,b,c 
*Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted me­































































































         
                                   
                                                           
                                           
                                                 
                             
               











GRADE Working Group grades of evidence
 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
 




Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
 


































































































































































aDowngraded one level because the trial(s) included in the analysis was/were at high risk of bias.
 
bDowngraded one level because the sample size was small.
 






























                                   
                                           
                                               
                               







































































Figure 1. A high resolution image is available at https://doi.org/10.5281/zenodo.3603056. The network plots showing the outcomes for which
 
network meta­analysis was performed. The size of the node (circle) provides a measure of the number of trials in which the particular Intervention
 
was included as one of the intervention groups. The thickness of the line provides a measure of the number of direct comparisons between two nodes
 
(Interventions) _: plus; Adverse events (proportion): the proportion of participants who developed 'any adverse events'; NoActiveIntervention: 'no
 



































































































































                               
                     
       
     
 
                           
     
     
                             




       
 
         











































































































Summary of findings 2. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis
 












Network geometry plots: Figure 1
 







(0.33 to 1.00) 
Network estimate 
79 fewer per 1000 
(123 fewer to 0 fewer) 
HR 0.74 48 fewer per 1000 
(0.49 to 1.09) (94 fewer to 17 more) 
Network estimate 
HR 0.61 71 fewer per 
(0.31 to 1.16) 1000 
Network estimate (126 fewer to 29 
more) 
— Very lowa,b,c Very lowa,b,c Very lowa,b,c 
— Based on 479 participants (3 RCTs) Based on 546 participants (4 RCTs) Based on 255 participants (3 RCTs) 






Rate ratio 1.66 
(0.98 to 2.90) 
Direct estimate 
87 more per 1000 
(3 fewer to 253 more) 
— — 
— Very lowa,b,c — — 
— Based on 353 participants (2 RCTs) — — 


































































































             




       
   





                             
             
     
   
             
                   
   
     
                     
     
     












































































(0.00 to 853.21) 
Network estimate 
1 more per 1000 
(201 fewer to 201 
more) 
OR 11.85 180 more per 1000 
(0.01 to 263023.85) (201 fewer to 201 
Network estimate more) 
— 
— Very lowa,b,c Very lowa,b,c — 
— Based on 299 participants (1 RCT) No direct RCTs — 






Rate ratio 1.15 
(0.98 to 1.34) 
Direct estimate 
78 more per 1000 
(9 fewer to 169 more) 
Rate ratio 0.74 138 fewer per 1000 
(0.59 to 0.94) (219 fewer to 33 fewer) 
Direct estimate 
Rate ratio 0.72 152 fewer per 
(0.49 to 1.05) 1000 
Direct estimate (270 fewer to 24 
more) 
— Very lowa,b,c Lowa,b Very lowa,b,c 






— HR 0.93 14 fewer per 1000 
(0.31 to 3.44) (126 fewer to 443 
Network estimate more) 
HR 0.62 69 fewer per 
(0.12 to 3.31) 1000 
Network estimate (160 fewer to 420 
more) 
— — Very lowa,b,c Very lowa,b,c 
— — Based on 68 participants (1 RCT) No direct RCT 






(0.13 to 4647.11) 
Direct estimate 
860 more per 1000 
(121 fewer to 860 
more) 
HR 0.16 117 fewer per 1000 
(0.00 to 1.56) (140 fewer to 79 more) 
Direct estimate 
HR 0.56 62 fewer per 
(0.02 to 60.64) 1000 
Direct estimate (138 fewer to 860 
more) 
— Very lowa,b,c Very lowa,b,c Very lowa,b,c 
































































































































         
   
           
   
           
 
                   
     
       
         
     
         
                                   
                                                           
                                           
                                                 
                             
               















































































































































































Rate ratio 0.61 
(0.46 to 0.80) 
Network estimate 
179 fewer per 1000 
(250 fewer to 94 fewer) 
Rate ratio 0.81 87 fewer per 1000 
(0.58 to 1.12) (192 fewer to 56 more) 
Network estimate 
— 
— Lowa,b Very lowa,b,c — 
— Based on 575 participants (3 RCTs) Based on 439 participants (3 RCTs) — 




— — MD –8.29 days 8.29 fewer days 
(–11.09 to –5.50) (11.09 fewer to 
Network estimate 5.5 fewer) 
— — — Lowa,b 
— — — Based on 60 participants (1 RCT) 
CrI: credible interval; HR: hazard ratio; MD: mean difference; OR: odds ratio; RCT: randomised clinical trial.
 
GRADE Working Group grades of evidence
 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
 




Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
 
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
 
aDowngraded one level because the trial(s) included in the analysis was/were at high risk of bias.
 
bDowngraded one level because the sample size was small.
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B A C K G R O U N D The overall incidence and prevalence of spontaneous bacterial
 




The liver is a complex organ with multiple functions including
 
carbohydrate metabolism, fat metabolism, protein metabolism,
 
drug metabolism, synthetic functions, storage functions, digestive
 
functions, excretory functions, and immunological functions (Read
 
1972). Liver cirrhosis is a liver disease in which the normal
 
microcirculation, the gross vascular anatomy, and the hepatic
 
architecture have been variably destroyed and altered, with fibrous
 
septa surrounding regenerated or regenerating parenchymal
 
nodules  (Tsochatzis 2014; NCBI 2018a). The major causes of liver
 
cirrhosis include excessive alcohol consumption, viral hepatitis,
 
non­alcohol related fatty liver disease, autoimmune liver diseases,
 
and metabolic liver diseases (Williams 2014; Ratib 2015; Setiawan
 
2016). The global prevalence of liver cirrhosis is difficult to
 
estimate as most estimates correspond to chronic liver disease
 
(which includes liver fibrosis and liver cirrhosis). In studies from
 
the US, the prevalence of chronic liver disease varies between
 
0.3%  and  2.1%  (Scaglione 2015;  Setiawan 2016);  in  the  UK,  the
 
prevalence was 0.1% in one study (Fleming  2008). In 2010, liver
 
cirrhosis caused an estimated 2% of all global deaths, equivalent
 
to one million deaths (Mokdad 2014). There is an increasing
 
trend of cirrhosis­related deaths in some countries, such as the
 
UK, while there is a decreasing trend in other countries, for
 
example France (Mokdad 2014; Williams 2014). The major cause of
 
complications and deaths in people with liver cirrhosis is due to the
 
development of clinically significant portal hypertension (hepatic
 
venous pressure gradient at least 10 mmHg) (de Franchis 2015).
 
Some of the clinical features of decompensation include jaundice,
 
coagulopathy, ascites, variceal bleeding, hepatic encephalopathy,
 
and renal failure (de Franchis 2015; McPherson 2016; EASL 2018).
 






Ascites is accumulation of free fluid in the abdomen (peritoneal
 
cavity) (NCBI  2018b), and it is a feature of liver decompensation
 
(Tsochatzis 2017; EASL 2018). Approximately 20% of people with
 
cirrhosis have ascites (D'Amico 2014). Approximately 1% to 4%
 
of people with cirrhosis develop ascites each year (D'Amico 2006;
 
D'Amico 2014). Ascites is the first sign of liver decompensation in
 
about a third of people with compensated liver cirrhosis (D'Amico
 
2014). When the ascitic fluid is infected with bacteria without
 
gastrointestinal disease or trauma, it is termed spontaneous
 
bacterial peritonitis. However, because of the poor sensitivity of
 
ascitic fluid culture, spontaneous bacterial peritonitis is diagnosed
 
by a polymorphonuclear leukocyte count of more than 250
 
per  mm3 in  the  ascitic  fluid  (Rimola  2000;  EASL  2018).  In  the
 
presence of haemorrhagic ascites (ascites with red blood cell
 
count of more than 10,000 per mm3), one polymorphonuclear
 
leukocyte should be subtracted for every red blood cell 250 to
 
account for the presence of blood in the ascitic fluid (Rimola
 
2000). Spontaneous bacterial peritonitis may or may not be
 
symptomatic, with symptoms of peritonitis such as abdominal
 




peritonitis in people with cirrhosis is difficult to estimate.
 
Approximately 2.5% of all hospitalisations of people with cirrhosis
 
are for spontaneous bacterial peritonitis (Devani 2019).  The
 
incidence of spontaneous bacterial peritonitis in people with
 




The short­term mortality (that is, death within 30 days of diagnosis
 
or death in hospital) after spontaneous bacterial peritonitis is
 
about 15% to 40% (Khan  2009;  Tandon 2011;  Devani 2019).
 
Spontaneous bacterial peritonitis is associated with significant
 
resource utilisation: one study conducted in the US showed that
 
the mean length of hospital stay was approximately six days and
 




Pathophysiology of spontaneous bacterial peritonitis
 
Increased bacterial translocation (gut bacteria or bacterial
 
products migrating outside the intestinal lumen) and decreased
 
local and systemic immune responses in people with cirrhosis
 




Description of the intervention
 
Antibiotic prophylaxis in the form of norfloxacin (fluoroquinolone)
 
is recommended for people without previous episodes of
 
spontaneous bacterial peritonitis but for people who have ascites
 
with low protein (primary prophylaxis), and for people with one
 
or more previous episodes of spontaneous bacterial peritonitis
 
(secondary prophylaxis) (EASL  2010;  Runyon 2013;  EASL  2018).
 
Alternative antibiotic prophylaxis recommended in these people
 
include ciprofloxacin (fluoroquinolone) and a combination of
 
trimethoprim and sulfamethoxazole (folic acid synthesis inhibitors)
 
(EASL 2010; Runyon 2013). Rifaximin is another antibiotic that has
 
been  tried  (Goel  2017), but it is not currently recommended by
 
the European Association for the Study of the Liver (EASL) for the
 
prophylaxis of spontaneous bacterial peritonitis (EASL 2018).
 
How the intervention might work
 
Different antibiotic classes have different mechanisms of action.
 
Cephalosporins inhibit bacterial cell wall synthesis (Yotsuji 1988).
 
Fluoroquinolones are type II topoisomerase inhibitors: type II
 
topoisomerases at appropriate levels are required for normal
 
cellular processes, and altering their levels leads to bacterial cell
 
death (Aldred 2014). Folic acid synthesis inhibitors inhibit folic acid,
 
which is necessary for DNA and bacterial cell replication (Gleckman
 




Why it is important to do this review
 
Spontaneous bacterial peritonitis is associated with significant
 
short­term mortality (Khan 2009; Tandon 2011; Devani 2019). It is
 
important to prevent spontaneous bacterial peritonitis in people
 
at high risk of developing it. This has to be balanced against the
 
development of drug­resistant spontaneous bacterial peritonitis,
 
which is difficult to treat. Active spontaneous bacterial peritonitis
 
may preclude liver transplantation as liver transplantation is not
 
performed during sepsis. Several different prophylactic antibiotic
 
treatments are available; however, their relative efficacy and
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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optimal combination are not known. There have been two
 
Cochrane Reviews on the role of prophylactic antibiotics in
 
people with cirrhosis  (Cohen 2009; Chavez­Tapia 2010); however,
 
there have been no previous network meta­analyses on the
 
topic. Network meta­analysis allows for a combination of direct
 
and indirect evidence and the ranking of different interventions
 
for different outcomes (Salanti  2011;  Salanti  2012).  With  this
 
systematic review and network meta­analysis, we aimed to
 
provide the best level of evidence for the benefits and harms
 
of different prophylactic antibiotic treatments for prevention of
 
spontaneous bacterial peritonitis in people with liver cirrhosis. If
 
it was not possible to perform this review with network meta­

analysis methods, we performed head­to­head comparison meta­

analysis whenever possible. We also presented results from direct
 






To compare the benefits and harms of different prophylactic
 
antibiotic treatments for prevention of spontaneous bacterial
 
peritonitis in people with liver cirrhosis using a network meta­

analysis and to generate rankings of the different prophylactic
 








We considered only randomised clinical trials (including cluster­

randomised trials and cross­over randomised trials) for this
 
network meta­analysis, irrespective of language, publication
 
status, or date of publication. We excluded studies of other designs
 
because of the risk of bias in such studies. Inclusion of indirect
 
observational evidence could weaken our network meta­analysis,
 






We included randomised clinical trials with adults with liver
 
cirrhosis, who were undergoing prophylactic treatment to prevent
 
spontaneous bacterial peritonitis. We excluded randomised clinical
 
trials in which participants had previously undergone liver
 
transplantation, or were receiving antibiotics for treatment of
 
spontaneous bacterial peritonitis or other purposes, for example,
 




We included any of the following different antibiotic interventions
 
for comparison with one another or against 'no active intervention',
 










•	 Other classes of antibiotics.
 
as a different treatment node. We considered variations in doses,
 
frequency, and duration of antibiotics as the same treatment node.
 




We evaluated the plausibility of the network meta­analysis
 
transitivity assumption by looking at the inclusion and exclusion
 
criteria in the studies. Transitivity assumption means that
 
participants included in the different trials with different antibiotic
 
prophylaxis can be considered to be a part of a multi­

arm randomised clinical trial and could potentially have been
 
randomised to any of the interventions (Salanti  2012). In other
 
words, any participant that meets the inclusion criteria is,
 
in principle, equally likely to be randomised to any of the
 
above eligible interventions. This necessitates that information
 
on potential effect­modifiers, such as the reason why the trial
 
participants were considered to be at high risk of developing
 
spontaneous bacterial peritonitis (ascites with low protein or
 
previous episodes of spontaneous bacterial peritonitis), is the same
 
across trials. Since there was no concern about the transitivity
 
assumption, we did not perform a separate meta­analysis for
 
people considered at high risk of spontaneous bacterial peritonitis
 
due to different reasons.
 




•	 All­cause mortality at maximal follow­up (time to death).
 
•	 Health­related quality of life using a validated scale such as the
 
EQ­5D or 36­Item Short Form Health Survey (SF­36) (EuroQol
 
2018; Optum 2018), at maximal follow­up
 
•	 Serious adverse events (during or within six months after
 
cessation of intervention). We defined a serious adverse
 
event as any event that would increase mortality; was life­

threatening; required hospitalisation; resulted in persistent or
 
significant disability; was a congenital anomaly/birth defect; or
 
any important medical event that might have jeopardised the
 
person or required intervention to prevent it (ICH­GCP  1997).
 
However, none of the trial authors defined serious adverse
 
events. Therefore, we used the list provided by trial authors for
 




*	 Proportion of people with one or more serious adverse event.
 




•	 Any adverse events (during or within six months after cessation
 
of intervention): we defined an adverse event as any untoward
 
medical occurrence not necessarily having a causal relationship
 
with the intervention but resulting in a dose reduction or
 
discontinuation of intervention (any time after commencement
 
of the intervention) (ICH­GCP 1997). However, none of the trial
 
authors defined 'adverse event'. Therefore, we used the list
 




*	 Proportion of people with one or more adverse event.
 
*	 Number of any adverse events per participant.
 
•	 Time to liver transplantation (maximal follow­up).
 
We used 'no active intervention' (either placebo or no antibiotic
 
treatment) as the reference group. We considered each antibiotic
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•	 Time to development of spontaneous bacterial peritonitis
 
(however, defined by study authors at maximal follow­up).





*	 Symptomatic spontaneous bacterial peritonitis.
 
















We chose the above outcomes based on their importance to
 
patients, having made a survey related to research priorities for
 
people with liver diseases (Gurusamy 2019), based on feedback of
 
the patient and public representatives of the project, and based
 








We searched the Cochrane Central Register of Controlled Trials
 
(CENTRAL; 2018, Issue 11) in the Cochrane Library, MEDLINE
 
Ovid, Embase Ovid, and Science Citation Index Expanded
 
(Web of Science) from inception to November 2018, without
 
applying any language restrictions (Royle 2003). We searched
 
for all possible comparisons formed by the interventions of
 
interest. To identify further ongoing or completed trials, we also
 
searched ClinicalTrials.gov, and the World Health Organization
 
International Clinical Trials Registry Platform (apps.who.int/
 
trialsearch/), which included various trial registers, including
 
ISRCTN and ClinicalTrials.gov. We also searched the European
 
Medical Agency (EMA) (www.ema.europa.eu/ema/) and US Food
 
and Drug Administration (FDA) (www.fda.gov) registries for
 
randomised clinical trials on 10 November 2018. The search
 




We searched the references of the identified trials and the existing
 
Cochrane Reviews on prophylactic antibiotic treatments in liver
 








Two review authors (KG and OK) independently identified trials
 
for inclusion by screening the titles and abstracts, and sought
 
full­text articles for any references identified by at least one of
 
the review authors for potential inclusion. We selected trials for
 
inclusion based on the full­text articles. We provided the list of
 
references that we excluded and the reasons for their exclusion in
 
the Characteristics of excluded studies table. We provided a list of
 
ongoing trials identified primarily through the search of the clinical
 
trial registers for further follow­up in the Characteristics of ongoing
 
studies table. We resolved any discrepancies through discussion.
 
It is well established that exclusion of non­randomised studies
 
increases the focus on potential benefits and reduces the focus
 
on the risks of serious adverse events and those of any adverse
 
events. However, because of the exponentially increased amount of
 
work required for non­randomised studies, we planned to register
 
and perform a new systematic review and meta­analysis of non­

randomised studies for adverse events if there was uncertainty in
 
the balance of benefits and harms of effective treatment(s). We
 
did not perform this because of the findings of the review, that is,
 
the credible intervals (CrI) were wide and there was considerable
 




Data extraction and management
 
Two review authors (KG and OK) independently extracted the
 
data in a piloted Microsoft Excel­based data extraction form (after
 
translation of non­English articles).





*	 number of participants randomised;
 
*	 number of participants included for the analysis;
 
*	 number of participants with events for binary outcomes,
 
mean and standard deviation for continuous outcomes,
 
number of events and the mean follow­up period for count
 
outcomes, and number of participants with events and the
 
mean follow­up period for time­to­event outcomes;
 
*	 natural logarithm of hazard ratio and its standard error, if
 
this was reported, rather than the number of participants
 




*	 definition of outcomes or scale used if appropriate.
 
•	 Data on potential effect modifiers:

*	 participant characteristics such as age, sex, presence of other
 
features of decompensation (hepatorenal syndrome, hepatic
 
encephalopathy, and variceal bleeding), the aetiology for
 








*	 length of follow­up;
 
*	 information related to 'Risk of bias' assessment (see
 




*	 year and language of publication;
 
*	 country in which the participants were recruited;
 
*	 year(s) in which the trial was conducted;
 
*	 inclusion and exclusion criteria.
 
We collected outcomes at maximum follow­up but also at short­

term (up to three months) and medium­term (from three months
 
to five years) if applicable.
 
We attempted to contact the trial authors in the case of unclear
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Assessment of risk of bias in included studies
 
We followed the guidance in the Cochrane Handbook for Systematic
 
Reviews of Interventions (Higgins 2011), to assess the risk of bias
 
in the included trials. Specifically, we assessed sources of bias as
 
defined below (Schulz  1995;  Moher  1998;  Kjaergard 2001;  Wood
 




•	 Low risk of bias: the study authors performed sequence
 
generation using computer random number generation or a
 
random number table. Drawing lots, tossing a coin, shuffling
 
cards, and throwing dice are adequate if performed by an
 
independent person not otherwise involved in the study. In
 
general, we classified the risk of bias as low if the method
 
used for allocation concealment suggested that it was extremely
 
likely that the sequence was generated randomly (e.g. use of
 
interactive voice response system).
 




•	 High risk of bias: the sequence generation method was not
 




•	 Low risk of bias: the participant allocations could not have
 
been foreseen in advance of, or during, enrolment. A central
 
and independent randomisation unit controlled allocation. The
 
investigators were unaware of the allocation sequence (e.g. if
 
the allocation sequence was hidden in sequentially numbered,
 
opaque, and sealed envelopes).
 
•	 Unclear risk of bias: the study authors did not describe
 
the method used to conceal the allocation so that the
 




•	 High risk of bias: it was likely that the investigators who assigned
 






•	 Low risk of bias: blinding of participants and key study personnel
 
was ensured, and it was unlikely that the blinding could have
 
been broken; or there was rarely no blinding or incomplete
 
blinding, but the review authors judged that the outcome was
 
not likely to be influenced by lack of blinding.
 
•	 Unclear risk of bias: insufficient information to permit a
 




•	 High risk of bias: no blinding or incomplete blinding, and the
 
outcome was likely to be influenced by lack of blinding; or
 
blinding of key study participants and personnel attempted, but
 
it was likely that the blinding could have been broken, and the
 




•	 Low risk of bias: blinding of outcome assessment was ensured,
 
and it was unlikely that the blinding could have been broken;
 
or rarely no blinding of outcome assessment, but the review
 
authors judged that the outcome measurement was not likely to
 
be influenced by lack of blinding.
 
•	 Unclear risk of bias: insufficient information to permit a
 




•	 High risk of bias: no blinding of outcome assessment, and
 
the outcome measurement was likely to be influenced by lack
 
of blinding; or blinding of outcome assessment, but likely
 
that the blinding could have been broken, and the outcome
 




•	 Low risk of bias: missing data were unlikely to make treatment
 
effects depart from plausible values. The study used sufficient
 
methods, such as multiple imputation, to handle missing data.
 
•	 Unclear risk of bias: there was insufficient information to assess
 
whether missing data in combination with the method used to
 
handle missing data were likely to induce bias on the results.
 






•	 Low risk of bias: the trial reported the following predefined
 
outcomes: at least one of the outcomes related to the main
 
reason for prophylactic antibiotic treatment of people with
 
cirrhosis, namely, all­cause mortality, incidence of spontaneous
 
bacterial peritonitis, and adverse events. If the original trial
 
protocol was available, the outcomes should have been those
 
called for in that protocol. If the trial protocol was obtained
 
from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought
 
should have been those enumerated in the original protocol if
 
the trial protocol was registered before or at the time that the
 
trial was begun. If the trial protocol was registered after the trial
 
was begun, those outcomes were not considered reliable.
 
•	 Unclear risk of bias: not all predefined, or clinically relevant and
 
reasonably expected, outcomes were reported fully; or it was
 
unclear whether data on these outcomes were recorded or not.
 
•	 High risk of bias: one or more predefined or clinically relevant
 
and reasonably expected outcomes were not reported, despite
 






•	 Low risk of bias: the trial appeared free of other components
 
that could have put it at risk of bias (e.g. inappropriate control
 




•	 Unclear risk of bias: the trial may or may not have been free of
 
other components that could have put it at risk of bias.
 
•	 High risk of bias: there were other factors in the trial that
 




We considered a trial to be at low risk of bias if we assessed
 
the trial to be at low risk of bias across all listed bias risk
 
domains. Otherwise, we considered trials to be at high risk of
 
bias. At the outcome level, we classified an outcome to be at
 
low risk of bias if the allocation sequence generation; allocation
 
concealment; blinding of participants, healthcare professionals,
 
and outcome assessors; incomplete outcome data; and selective
 
outcome reporting (at the outcome level) were at low risk of bias
 
for objective and subjective outcomes (Savović 2018). We did not
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use additional items for cross­over or clustered RCTs, as we did not
 
identify any that met the inclusion criteria.
 




For dichotomous variables (e.g. proportion of participants with
 
serious adverse events or any adverse events), we calculated
 
the odds ratio (OR) with 95% credible interval (CrI) (or Bayesian
 
confidence interval) (Severini 1993). For continuous variables (e.g.
 
health­related quality of life reported on the same scale), we
 
calculated the mean difference (MD) with 95% CrI. We planned to
 
use standardised mean difference (SMD) values with 95% CrI for
 
health­related quality of life if the included trials had used different
 
scales. If we calculated the SMD, we planned to convert it to a
 
common scale, for example, EQ5D or SF­36 (using the standard
 
deviation of the common scale) for the purpose of interpretation.
 
For count outcomes (e.g. number of serious adverse events or
 
number of any adverse events), we calculated the rate ratio (RaR)
 
with 95% CrI. This assumes that the events were independent of
 
each other, that is, if a person has had an event they are not at
 
an increased risk of further outcomes, which is the assumption in
 
Poisson likelihood. For time­to­event data (e.g. all­cause mortality
 






We estimated the ranking probabilities for all interventions of
 
being at each possible rank for each intervention for each outcome
 
when network meta­analysis was performed. We obtained the
 
surface under the cumulative ranking curve (SUCRA) (cumulative
 
probability), rankogram, and relative ranking table with CrI for
 
the ranking probabilities for each outcome when network meta­

analysis was performed (Salanti 2011; Chaimani 2013).
 
Unit of analysis issues
 
The unit of analysis was the participant receiving antibiotic
 
prophylaxis for spontaneous bacterial peritonitis according to
 






If we had identified any cluster­randomised clinical trials, we
 
planned to include them provided that the effect estimate adjusted
 
for cluster correlation was available or if there was sufficient
 
information available to calculate the design effect (which would
 
allow us to take clustering into account). We also planned to assess
 
additional domains of risk of bias for cluster­randomised trials
 




Cross­over randomised clinical trials
 
If we had identified any cross­over randomised clinical trials, we
 
planned to include only the outcomes after the period of first
 




Trials with multiple intervention groups
 
We collected data for all trial intervention groups that met the
 
inclusion criteria. The codes we used for analysis accounted for the
 




Dealing with missing data
 
We performed an intention­to­treat analysis whenever possible
 
(Newell 1992); otherwise, we used the data available to us. When
 
intention­to­treat analysis was not used and the data were not
 
missing at random (e.g. treatment was withdrawn due to adverse
 
events or duration of treatment was shortened because of lack of
 
response and such participants were excluded from analysis), it
 
could lead to biased results; therefore, we conducted best­worst
 
case scenario analysis (assuming a good outcome in intervention
 
group and bad outcome in control group) and worst­best case
 
scenario analysis (assuming a bad outcome in intervention group
 
and good outcome in control group) as sensitivity analyses
 
whenever possible for binary and time­to­event outcomes, where
 
binomial likelihood was used.
 
For continuous outcomes, we planned to impute the standard
 
deviation from P values, according to guidance in the Cochrane
 
Handbook for Systematic Reviews of Interventions (Higgins  2011).
 
If the data were likely to be normally distributed, we planned
 
to use the median for meta­analysis when the mean was not
 
available; otherwise, we planned to simply provide a median and
 
interquartile range of the difference in medians. If it was not
 
possible to calculate the standard deviation from the P value or the
 
confidence intervals, we planned to impute the standard deviation
 
using the largest standard deviation in other trials for that outcome.
 
This form of imputation can decrease the weight of the study for
 
calculation of MDs and may bias the effect estimate to no effect for
 




We assessed clinical and methodological heterogeneity by carefully
 
examining the characteristics and design of included trials. We
 
also planned to assess the presence of clinical heterogeneity
 
by comparing effect estimates (see Subgroup analysis and
 
investigation of heterogeneity) in trial reports of different drug
 
dosages, reasons why the trial participants were considered to
 
be at high risk of developing spontaneous bacterial peritonitis
 
(ascites with low protein or previous episodes of spontaneous
 
bacterial peritonitis), different aetiologies for cirrhosis (e.g. alcohol­

related liver disease, viral liver diseases, autoimmune liver disease),
 
and based on the cointerventions (e.g. both groups received
 




We assessed statistical heterogeneity by comparing the results
 
of the fixed­effect model meta­analysis and the random­effects
 
model meta­analysis, between­study standard deviation (tau2,
 
and comparing this with values reported in a study of the
 
distribution of between­study heterogeneity estimates) (Turner
 
2012), and by calculating the I2 statistic (Jackson  2014)  using
 
Stata 15.1. If we identified substantial clinical, methodological, or
 
statistical heterogeneity, we planned to explore and address the
 




Assessment of transitivity across treatment comparisons
 
We assessed the transitivity assumption by comparing the
 
distribution of the potential effect modifiers (clinical: reasons
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why the trial participants were considered to be at high risk
 
of developing spontaneous bacterial peritonitis, that is, ascites
 
with low protein or previous episodes of spontaneous bacterial
 
peritonitis; methodological: risk of bias, year of randomisation,
 
duration of follow­up) across the different pairwise comparisons.
 
Assessment of reporting biases
 
For the network meta­analysis, we planned to perform a
 
comparison­adjusted funnel plot. However, to interpret a
 
comparison­adjusted funnel plot, it is necessary to rank the studies
 
in a meaningful way as asymmetry may be due to small sample
 
sizes in newer studies (comparing newer treatments with older
 
treatments) or higher risk of bias in older studies (comparing
 
older treatments with placebo) (Chaimani 2012). As there was no
 
meaningful way in which to rank these studies (i.e. there was no
 
specific change in the risk of bias in the studies, sample size, or the
 
control group used over time), we judged the reporting bias by the
 
completeness of the search (Chaimani 2012). We also considered
 




Methods for indirect and mixed comparisons
 
We conducted network meta­analyses to compare multiple
 
interventions simultaneously for each of the primary and
 
secondary outcomes. Network meta­analysis combines direct
 
evidence within trials and indirect evidence across trials (Mills
 
2012). We obtained a network plot to ensure that the trials were
 
connected by interventions using Stata 15.1 (Chaimani  2013).
 
We excluded any trials that were not connected to the network
 
from the network meta­analysis, and we reported only the direct
 
pairwise meta­analysis for such comparisons. We summarised
 
the population and methodological characteristics of the trials
 
included in the network meta­analysis in a table based on pairwise
 
comparisons. We conducted a Bayesian network meta­analysis
 
using the Markov chain Monte Carlo method in OpenBUGS 3.2.3,
 
according to guidance from the National Institute for Health and
 
Care Excellence (NICE) Decision Support Unit (DSU) documents
 
(Dias  2016). We modelled the treatment contrast (i.e. log OR
 
for binary outcomes, MD or SMD for continuous outcomes, log
 
RaR for count outcomes, and log HR for time­to­event outcomes)
 
for any two interventions ('functional parameters') as a function
 
of comparisons between each individual intervention and the
 
reference group ('basic parameters'), using appropriate likelihood
 
functions and links (Lu 2006). We used binomial likelihood and
 
logit link for binary outcomes, Poisson likelihood and log link for
 
count outcomes, binomial likelihood and complementary log­log
 
link (a semiparametric model which excludes censored individuals
 
from the denominator of 'at risk' individuals at the point when they
 
were censored) for time­to­event outcomes, and normal likelihood
 
and identity link for continuous outcomes. We used 'no active
 
intervention' as the reference group across the networks. We used
 
a fixed­effect model and random­effects model for the network
 
meta­analysis. We reported both models for comparison with the
 
reference group in a forest plot when the results were different
 
between the models. For each pairwise comparison in a table, we
 
reported the fixed­effect model if the two models reported similar
 
results; otherwise, we reported the more conservative model, that
 




We used a hierarchical Bayesian model using three different sets
 
of initial values to start the simulation­based parameter estimation
 
to assist with the assessment of convergence, employing codes
 
provided by the NICE DSU (Dias  2016).  We  used  a  normal
 
distribution with large variance (10,000) for treatment effect priors
 
(vague or flat priors) centred at no effect. For the random­effects
 
model, we used a prior distributed uniformly (limits: 0 to 5) for
 
the between­trial standard deviation and assumed this variability
 
would be the same across treatment comparisons (Dias 2016). We
 
used a 'burn­in' of 30,000 iterations, checked for convergence (of
 
effect estimates and between­study heterogeneity) visually (i.e.
 
checked whether the values in different chains mix very well by
 
visualisation), and ran the models for another 10,000 iterations
 
to obtain effect estimates. If we did not obtain convergence, we
 
increased the number of iterations for the 'burn­in' and used the
 
'thin' and 'over relax' functions to decrease the autocorrelation.
 
If we still did not obtain convergence, we planned to use
 
alternate initial values and priors employing methods suggested
 
by van Valkenhoef 2012. We estimated the probability that each
 






We assessed inconsistency (statistical evidence of the violation
 
of transitivity assumption) by fitting both an inconsistency model
 
and a consistency model. We used inconsistency models employed
 
in the NICE DSU manual, as we used a common between­study
 
standard deviation (Dias  2014). In addition, we used design­

by­treatment full interaction model and inconsistency factor
 
plots to assess inconsistency when applicable (Higgins  2012;
 
Chaimani 2013). We used Stata 15.1 to create inconsistency factor
 
plots. In the presence of inconsistency, we planned to assess
 
whether the inconsistency was due to clinical or methodological
 
heterogeneity by performing separate analyses for each of the
 
different subgroups mentioned in the Subgroup analysis and
 
investigation of heterogeneity section.
 
If there was evidence of inconsistency, we planned to identify areas
 
in the network where substantial inconsistency might be present
 
in terms of clinical and methodological diversities between trials,
 
and, when appropriate, limited network meta­analysis to a more
 








Subgroup analysis and investigation of heterogeneity
 
We planned to assess the differences in the effect estimates
 
between the following subgroups, and investigate heterogeneity
 
and inconsistency using meta­regression using the codes provided
 
in the NICE DSU guidance (Dias 2012a), if we included a sufficient
 
number of trials (when there were at least two trials in at least two of
 
the subgroups) and when the interaction term could be calculated.
 




•	 Trials at low risk of bias (risk of bias in all domains were low)
 
compared to trials at high risk of bias (risk of bias was unclear or
 
high in at least one of the domains).
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•	 The reasons why the trial participants were considered to be
 
at high risk of developing spontaneous bacterial peritonitis
 




•	 The aetiology for cirrhosis (e.g. alcohol­related liver disease,
 
viral liver diseases, autoimmune liver disease).
 




•	 Different types of cointervention (e.g. both groups received
 




•	 The period of follow­up (short­term: up to three months,
 
medium term: more than three months to five years, long­term:
 
more than five years).
 
•	 The definition used by authors for serious adverse events and
 
any adverse event (ICH­GCP 1997) versus other definitions.
 
We planned to calculate a single common interaction term
 
(which assumed each relative treatment effect versus a common
 
comparator treatment ('no active intervention') was impacted
 
in the same way by the covariate in question) when applicable
 
(Dias  2012a). If the 95% CrI of the interaction term did not
 
overlap zero, we would have considered this statistically significant
 






If there were postrandomisation dropouts, we reanalysed the
 
results using the best­worst case scenario and worst­best case
 
scenario as sensitivity analyses whenever possible. We also
 
planned to perform a sensitivity analysis excluding the trials in
 
which mean or standard deviation (or both) were imputed, and
 
we planned to use the median standard deviation in the trials to
 




We followed the PRISMA­NMA statement while reporting (Hutton
 
2015). We presented the effect estimates with 95% CrI for each
 
pairwise comparison calculated from the direct comparisons and
 
network meta­analysis. We originally planned to present the
 
cumulative probability of the treatment ranks (i.e. the probability
 
that the intervention was within the top two, the probability
 
that the intervention was within the top three, etc.), but we did
 
not present these because of the sparse data which can lead to
 
misinterpretation of results due to large uncertainty in the rankings
 
(the CrI was 0 to 1 for all the ranks) in graphs (SUCRA) (Salanti
 
2011). We plotted the probability that each intervention was best,
 
second best, third best, etc. for each of the different outcomes
 
(rankograms), which are generally considered more informative
 
(Salanti 2011; Dias 2012b), but we did not present these because of
 
the sparse data which can lead to misinterpretation of results due to
 
large uncertainty in the rankings (the CrI was 0 to 1 for all the ranks).
 
We uploaded all the raw data and the codes used for analysis in The
 






We presented 'Summary of findings' tables for all the primary
 
and secondary outcomes (see Primary outcomes;  Secondary
 
outcomes). We followed the approach suggested by Yepes­Nunez
 
and colleagues (Yepes­Nunez 2019). First, we calculated the direct
 
and indirect effect estimates (when possible) and 95% CrI using
 
the node­splitting approach (Dias  2010), that is, calculating the
 
direct estimate for each comparison by including only trials in
 
which there was direct comparison of interventions and the indirect
 
estimate for each comparison by excluding the trials in which there
 
was direct comparison of interventions (and ensuring a connected
 
network). Next, we rated the quality of direct and indirect effect
 
estimates using GRADE methodology which takes into account the
 
risk of bias, inconsistency (heterogeneity), directness of evidence
 
(including incoherence, the term used in GRADE methodology
 
for inconsistency in network meta­analysis), imprecision, and
 
publication bias (Guyatt 2011). We then presented the relative and
 
absolute estimates of the meta­analysis with the best certainty of
 
evidence (Yepes­Nunez 2019). We also presented the 'Summary of
 
findings' tables in a second format presenting all the outcomes for
 
selected interventions (Yepes­Nunez 2019): we selected the three
 
interventions (rifaximin, norfloxacin, and ciprofloxacin) which most
 
trials compared (Table 1).
 
Recommendations for future research
 
We provided recommendations for future research regarding the
 
population, intervention, control, outcomes, period of follow­up,
 
and study design, based on the uncertainties that we identified
 






Results of the search
 
We identified 1322 references through electronic searches of
 
CENTRAL (183 references), MEDLINE Ovid (501 references), Embase
 
Ovid (238 references), Science Citation Index Expanded (316
 
references), ClinicalTrials.gov (35 references) and WHO Trials
 
register (49 references). After removing duplicate references, there
 
were 1050 references. We excluded 978 clearly irrelevant references
 
through reading titles and abstracts. We did not identify any
 
additional eligible trial by reference searching or by searching
 
the EMA or FDA. We retrieved 72 full­text references for further
 
assessment in detail. We excluded 22 references (21 studies)
 
for the reasons stated in the Characteristics of excluded studies
 
table. Thus, we included 29 trials described in 50 references
 
(Characteristics of included studies table). The reference flow is
 
shown in Figure 2.
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Figure 2. Study flow diagram.
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Alvarez 2005; Fernandez 2007; Terg 2008; Bass 2010; Ali 2014; Lontos
 
2014;  Mostafa 2014;  Tellez­Avila 2014;  Baik  2015;  Moreau 2015;
 
Mostafa 2015; Nawaz 2015; Abdel Motelleb 2016; Assem 2016; Bajaj
 
2016;  Elfert 2016;  Latif  2016;  Ibrahim 2017;  Kimer  2017;  Praharaj
 
2017; Yim 2018). A total of 3896 participants were randomised to
 
different interventions. The number of participants ranged from 20
 
to 518. A total of 2587 participants from 23 trials provided data for
 
one or more outcomes (Ginés  1990;  Rolachon 1995;  Singh  1995;
 
Grangie 1998; Trespi 1999; Madrid 2001; Bauer 2002; Alvarez 2005;
 
Fernandez 2007; Terg 2008; Bass 2010; Ali 2014; Lontos 2014; Tellez­

Avila 2014;  Baik  2015;  Moreau 2015;  Mostafa 2015;  Nawaz 2015;
 
Assem 2016; Elfert 2016; Kimer 2017; Praharaj 2017; Yim 2018). The
 
mean or median age in the trials ranged from 42 to 63 years in the
 




Bauer 2002; Alvarez 2005; Fernandez 2007; Terg 2008; Bass 2010;
 




proportion of females ranged from 16.7% to 61.1% in the trials that
 
reported this information (Ginés 1990; Rolachon 1995; Miglio 1997;
 
Grangie 1998; Trespi 1999; Madrid 2001; Bauer 2002; Alvarez 2005;
 
Fernandez 2007; Bass 2010; Ali  2014;  Lontos 2014; Mostafa 2014;
 




The follow­up period in the trials ranged from 1 to 12 months. Five
 
trials had short­term follow­up (Singh 1995; Baik 2015; Latif 2016;
 
Ibrahim 2017; Kimer 2017); 24 trials had medium­term follow­up
 
(Ginés 1990; Rolachon 1995; Miglio 1997; Grangie 1998; Trespi 1999;
 
Madrid 2001; Bauer 2002; Alvarez 2005; Fernandez 2007; Terg 2008;
 
Bass 2010; Ali 2014; Lontos 2014; Mostafa 2014; Tellez­Avila 2014;
 
Moreau 2015;  Mostafa 2015;  Nawaz 2015;  Abdel Motelleb 2016;
 
Assem 2016; Bajaj 2016; Elfert 2016; Praharaj 2017; Yim 2018); and
 
none of the trials had long­term follow­up.
 
Nine trials reported the proportion of participants who had other
 
features of decompensation: in five trials, all the participants
 
had other features of decompensation (Miglio  1997;  Bass  2010;
 
Ali  2014;  Nawaz 2015;  Abdel Motelleb 2016); in the remaining
 
four trials, the proportion of participants who had other features
 
of decompensation ranged from 13.8% to 65.8% (Bauer  2002;
 
Fernandez 2007; Assem 2016; Ibrahim 2017).
 
Seven trials reported the proportion of participants who had ascites
 
with low protein: in one trial, none of the participants had ascites
 
with low protein (Tellez­Avila 2014); in four trials, all the participants
 
had ascites with low protein (Rolachon 1995;  Fernandez 2007;
 
Terg 2008; Abdel Motelleb 2016); in the remaining two trials, the
 
proportion of participants who had ascites with low protein ranged
 
from 49.1% to 86.3% (Alvarez 2005; Lontos 2014).
 
Eighteen trials reported the proportion of participants who had
 
primary prophylaxis: in six trials, none of the participants had
 
primary prophylaxis (Ginés  1990;  Bauer  2002;  Mostafa 2014;
 
Mostafa 2015;  Elfert 2016;  Praharaj 2017);  in  eight  trials,  all  the
 
participants had primary prophylaxis (Grangie 1998;  Fernandez
 
2007;  Terg 2008;  Tellez­Avila 2014;  Abdel Motelleb 2016;  Assem
 
2016; Bajaj  2016;  Ibrahim 2017); in the remaining four trials, the
 
proportion of participants who had primary prophylaxis ranged
 




Nineteen trials reported the proportion of participants who had
 
alcohol­related cirrhosis: in three trials, none of the participants
 
had alcohol­related cirrhosis (Mostafa 2014;  Mostafa 2015;  Latif
 
2016); in one trial, all the participants had alcohol­related cirrhosis
 
(Trespi 1999); in the remaining 15 trials, the proportion of
 
participants who had alcohol­related cirrhosis ranged from 3.2%
 
to 91.7% (Ginés  1990;  Rolachon 1995;  Singh  1995;  Miglio  1997;
 
Grangie 1998; Madrid 2001; Bauer 2002; Alvarez 2005;  Fernandez
 




Sixteen trials reported the proportion of participants who had viral­

related cirrhosis: in one trial, none of the participants had viral­

related cirrhosis (Trespi 1999); in two trials, all the participants
 
had viral­related cirrhosis (Mostafa 2014;  Mostafa 2015);  in  the
 
remaining 13 trials, the proportion of participants who had viral­









Six trials reported the proportion of participants who had
 
autoimmune disease­related cirrhosis: in four trials, none of the
 
participants had autoimmune disease­related cirrhosis (Trespi
 
1999;  Mostafa 2014;  Tellez­Avila 2014;  Mostafa 2015);  in  the
 
remaining two trials, the proportion of participants who had
 




Nineteen trials reported the proportion of participants who had
 
other­causes for cirrhosis: in two trials, none of the participants
 
had other­causes for cirrhosis (Trespi 1999;  Mostafa 2015);  in
 
the remaining 17 trials, the proportion of participants who had
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Bauer 2002; Alvarez 2005; Fernandez 2007; Ali 2014; Lontos 2014;
 




In the only trial that reported the proportion of participants
 
who had treatment for ascites in addition to antibiotics, all the
 




The trials compared nine antibiotic regimens (ciprofloxacin,
 
neomycin, norfloxacin, norfloxacin plus neomycin, norfloxacin plus
 
rifaximin, rifaximin, rufloxacin, sparfloxacin, sulfamethoxazole plus
 
trimethoprim), and 'no active intervention'.
 
Twenty­three trials reported one or more outcomes for this review
 
(Ginés  1990;  Rolachon 1995;  Singh  1995;  Grangie 1998;  Trespi
 
1999;  Madrid  2001;  Bauer  2002;  Alvarez 2005;  Fernandez 2007;
 
Terg 2008;  Bass  2010;  Ali  2014;  Lontos 2014;  Tellez­Avila 2014;
 
Baik 2015; Moreau 2015; Mostafa 2015; Nawaz 2015; Assem 2016;
 
Elfert 2016; Kimer 2017; Praharaj 2017; Yim 2018). The important
 
characteristics, potential effect modifiers, and follow­up in each
 
trial is reported in Table 1. Overall, there did not seem to be any
 
systematic differences between the comparisons.
 
Funding: the source of funding for five trials was industrial
 
organisations who could benefit from the results of the study (Ginés
 
1990;  Bass  2010;  Tellez­Avila 2014; Moreau 2015;  Bajaj  2016);  six
 
trials were funded by neutral organisations who had no vested
 
interests in the results of the study (Madrid 2001; Fernandez 2007;
 
Terg 2008; Assem 2016; Kimer 2017; Yim 2018); the source of funding
 
for the remaining 18 trials was unclear (Rolachon 1995; Singh 1995;
 
Miglio 1997; Grangie 1998; Trespi 1999; Bauer 2002; Alvarez 2005; Ali
 
2014; Lontos 2014; Mostafa 2014; Baik 2015; Mostafa 2015; Nawaz
 






We excluded 21 studies, with reasons (Anonymous 1971; Boccardi
 
1974;  Rimola  1985;  Schubert  1991;  Henrion  1992;  Pateron 1992;
 
Bode  1997;  Gerbes  1997;  Novella 1997;  Gines  1998;  Assy 2005;
 
Bendtsen 2005;  Lata 2005;  Anonymous  2006;  Vibert  2008;  Kemp
 
2009;  Jalan  2010;  Siddique  2010; Bajaj  2012; Gupta 2013; Kumar
 
2014; see Characteristics of excluded studies table).
 
Risk of bias in included studies
 
The risk of bias is summarised in Figure 3, Figure 4, and Table 2. Two
 
trials were at low risk of trials in all domains (Terg 2008; Kimer 2017).
 
All the remaining trials were at unclear or high risk of bias in at least
 
one of the domains and were considered to be at high risk of bias.
 
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
 
across all included studies.
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Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Eight trials were at low risk of sequence generation bias (Miglio
 
1997; Fernandez 2007; Terg 2008; Lontos 2014; Assem 2016; Elfert
 
2016;  Kimer  2017;  Yim  2018); the remaining 21 trials, which did
 
not provide sufficient information, were at unclear risk of sequence
 
generation bias (Ginés 1990; Rolachon 1995; Singh 1995; Grangie
 








Nine trials were at low risk of allocation concealment bias (Miglio
 
1997;  Fernandez 2007;  Terg 2008;  Lontos 2014;  Tellez­Avila 2014;
 
Assem 2016; Elfert 2016; Kimer 2017; Yim 2018); the remaining 20
 
trials, which did not provide sufficient information, were at unclear
 












Twelve trials were at low risk of blinding of trial participants and
 
healthcare providers bias (Ginés 1990; Rolachon 1995; Miglio 1997;
 




which did not provide sufficient information, were at unclear risk of
 
blinding of participants and healthcare providers bias (Singh 1995;
 
Trespi 1999; Madrid 2001; Alvarez 2005; Mostafa 2014; Baik 2015;
 
Mostafa 2015; Nawaz 2015; Abdel Motelleb 2016; Latif 2016; Ibrahim
 
2017; Praharaj 2017); the remaining five trials were at high risk of
 
blinding of participants and healthcare providers bias (Bauer 2002;
 
Lontos 2014; Assem 2016; Elfert 2016; Yim 2018).
 
The risk of blinding of outcome assessors' bias was the same as the
 






Nine trials were at low risk of incomplete outcome data bias (Singh
 
1995; Grangie 1998; Bauer 2002; Terg 2008; Bass 2010; Mostafa 2014;
 
Tellez­Avila 2014; Elfert 2016; Kimer 2017); the remaining 20 trials
 
were at unclear risk of incomplete outcome data bias, because
 
it was not clear whether there were postrandomisation dropouts
 
or whether the postrandomisation dropouts were related to the
 
outcomes (if there were postrandomisation dropouts) (Ginés 1990;
 
Rolachon 1995; Miglio 1997; Trespi 1999; Madrid 2001; Alvarez 2005;
 
Fernandez 2007;  Ali  2014;  Lontos 2014;  Baik  2015; Moreau 2015;
 






Eleven trials were at low risk of selective outcome reporting bias
 
(Ginés 1990; Singh 1995; Alvarez 2005; Fernandez 2007; Terg 2008;
 
Bass 2010; Lontos 2014; Tellez­Avila 2014; Assem 2016; Elfert 2016;
 
Kimer  2017), as the protocol published prior to recruitment was
 
available and the outcomes were reported or the important clinical
 
outcomes expected to be reported in such trials were reported;
 
the remaining 18 trials were at high risk of selective outcome
 
reporting bias, as the trials did not report the reasonably expected
 
clinical outcomes in the absence of a protocol published prior to
 








Other potential sources of bias
 




See: Summary of findings for the main comparison Antibiotic
 
prophylaxis to prevent spontaneous bacterial peritonitis in people
 
with liver cirrhosis; Summary of findings 2 Antibiotic prophylaxis
 




The network plots (where relevant) are available in Figure 1. The
 
inconsistency factor plots (where relevant) are available in Figure
 
5. The differences in the fixed­effect versus random­effects model
 
where relevant are available in Figure 6. The model fit is available
 
in Table 2. The effect estimates are available in Table 3.
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Figure 5. Inconsistency factor plots showing the inconsistency factors for the outcomes with direct and indirect
 
evidence available for one or more comparisons. There was no evidence of inconsistency for all­cause mortality and
 
other decompensation, but there was evidence of inconsistency for adverse events number and SBP development.
 
SBP: spontaneous bacterial peritonitis.
 
Note: The full images are available at doi.org/10.5281/zenodo.3457886.
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Figure 6. Forest plots showing the outcomes for which the random­effects model were different from the fixed­

effect model. The more conservative random­effects model was used.
 
The 95% CrIs of the probability ranks were wide and included 0
 
and 1 in all the comparisons for all the primary and secondary
 
outcomes. This was probably because of the sparse data from
 
small trials. Therefore, we did not present the ranking probabilities
 
(in a table), rankograms, and SUCRA plots as we considered that
 
presenting this information would be unhelpful and potentially
 




The certainty of evidence was very low for all the comparisons. This
 
was because 27 trials (all except Terg 2008 and Kimer 2017) were
 
at unclear or high risk of bias for one or more risk of bias domains
 
at the outcome level (downgraded one level), the sample size
 
was small (downgraded one level), and the wide CrIs overlapping
 








Alvarez 2005; Fernandez 2007; Terg 2008; Bass 2010; Ali 2014; Lontos
 
2014;  Tellez­Avila 2014;  Moreau 2015;  Assem 2016;  Elfert 2016;
 
Kimer  2017;  Yim  2018). These trials compared seven treatments
 
(ciprofloxacin, neomycin, norfloxacin, norfloxacin plus neomycin,
 
norfloxacin plus rifaximin, rifaximin, rufloxacin, sparfloxacin,
 
sulfamethoxazole plus trimethoprim, and no active intervention).
 
All the trials were connected to the network.
 
There was no evidence of inconsistency according to model fit
 
(Table 2), 'between­design' variance (0.17, 95% CrI 0.00 to 3.49),
 
or in the inconsistency factor plot (Figure 5). The random­effects
 
model was used because it was more conservative, even though the
 
model fit was similar to the fixed­effect model. The 'between­study
 
variance' was 0.03 (95% CrI 0.00 to 0.39).
 
There was no evidence of differences in any of the direct
 
comparisons or in the network meta­analysis (i.e. there was no
 
statistically significant difference in any of the comparisons) (all
 
comparisons: very low certainty evidence) (Table 3). The sensitivity
 
analysis indicated that the different scenarios (best­worst and
 
worst­best scenarios) for imputing missing data indicated different
 
interpretation of results; therefore, the results were sensitive to
 




Health­related quality of life
 
None of the trials reported health­related quality of life.
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Two trials (332 participants) reported proportion of people with
 
serious adverse events (Mostafa 2015;  Elfert 2016). Both trials
 
compared rifaximin versus norfloxacin. There were no serious
 
events in either group in the two trials (Mostafa 2015; Elfert 2016)
 
(very low certainty evidence).
 
Five trials (797 participants) reported number of serious adverse
 
events per participant (Bass 2010; Mostafa 2015; Elfert 2016; Kimer
 
2017; Yim 2018). These trials compared four treatments. Two trials
 
(332 participants) comparing rifaximin and norfloxacin were not
 
connected to the network because they had zero events in both
 
arms (Mostafa 2015; Elfert 2016); one trial was not connected to the
 
network because of unconnected treatments once the trials with
 
zero events in both arms was excluded (Yim 2018): therefore, these
 
three trials were excluded from the network. Only two treatments
 
(rifaximin versus no active intervention) were compared in the
 
remaining two trials. Therefore, network meta­analysis or checking
 
for inconsistency was not applicable. The fixed­effect model was
 
used because it had equivalent results and model fit as random­

effects model. There was no evidence of differences (i.e. there was
 
no statistically significant difference in any of the comparisons)
 
between rifaximin and no active intervention (RaR 1.66, 95% CrI
 
0.98 to 2.90; 2 trials, 353 participants; very low­certainty evidence)
 
or between ciprofloxacin and norfloxacin (RaR 1.63, 95% CrI 0.85 to
 




Three trials (631 participants) reported proportion of people with
 
any adverse events (Bass 2010; Mostafa 2015; Elfert 2016). These
 
trials compared three treatments. All the trials were connected
 
to the network. There were no triangular or quadrangular loops;
 
therefore, inconsistency was not checked. The random­effects
 
model was used because it was more conservative and there
 
was significant between­study heterogeneity (the 'between­study
 
variance' was 9.28, 95% CrI 0.12 to 24.10), even though the model
 
fit was similar to the fixed­effect model. There was no evidence
 
of differences in any of the direct comparisons or network meta­

analysis (i.e. there was no statistically significant difference in any
 
of the comparisons) (Table 3). There was no change in the results by
 




Fifteen trials (1734 participants) reported number of any adverse
 
events per participant (Ginés  1990;  Rolachon 1995;  Singh  1995;
 
Grangie 1998; Bauer 2002; Alvarez 2005; Fernandez 2007; Terg 2008;
 
Bass 2010; Lontos 2014; Tellez­Avila 2014; Baik 2015; Moreau 2015;
 
Assem 2016; Kimer 2017). These trials compared seven treatments.
 
All the trials were connected to the network. There was evidence
 
of inconsistency according to model fit, inconsistency factor (one
 
loop involving 'no active intervention', norfloxacin, and rifaximin),
 
and the 'between­design' variance (1.51, 95% CrI 0.03 to 18.25);
 
therefore, there is uncertainty in the validity of the network meta­

analysis results. The direct comparisons are more reliable. We did
 
not attempt to exclude the studies causing the inconsistency since
 
the three interventions in the inconsistent loop were the three main
 
interventions compared in this review and the differences may
 
be due to the different definitions used for adverse events across
 
the comparisons (none of the trials used the ICH­GCP definition).
 
Therefore, only the direct comparison results are presented. The
 
fixed­effect model was used because it had equivalent results and
 
model fit as random­effects model.
 




•	 Norfloxacin versus 'no active intervention': RaR 0.74 (95% CrI
 
0.59 to 0.94; 4 trials, 546 participants; low­certainty evidence).
 
•	 Sulfamethoxazole plus trimethoprim versus 'no active
 




There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant).

•	 Rifaximin versus 'no active intervention': RaR 1.15 (95% CrI 0.98
 
to 1.34; 3 trials, 418 participants; very low­certainty evidence).
 
•	 Ciprofloxacin versus 'no active intervention': RaR 0.72 (95%
 




•	 Norfloxacin versus rifaximin: RaR 1.18 (95% CrI 0.88 to 1.58; 1
 
trial, 160 participants; very low­certainty evidence).
 
•	 Norfloxacin plus rifaximin versus rifaximin: RaR 0.95 (95%
 




•	 Sulfamethoxazole plus trimethoprim versus norfloxacin: RaR
 




•	 Norfloxacin plus rifaximin versus norfloxacin: RaR 0.81 (95%
 




•	 Rufloxacin versus norfloxacin: RaR 1.60 (95% CrI 0.79 to 3.54; 1
 




Four trials (339 participants) reported liver transplantation (Bauer
 
2002;  Fernandez 2007;  Lontos 2014;  Yim  2018).  These  trials
 
compared five treatments. There were 55 liver transplants in total
 
(16.2%). One trial was not connected to the network because
 
it was the only trial for the comparison and had zero events
 
in  one  of  the  arms  (Bauer  2002), and therefore excluded from
 
the network. The network had four connected treatments. The
 
three connected trials included 260 participants. There were no
 
triangular or quadrangular loops; therefore, inconsistency was not
 
checked. Only one trial was included in each of the comparisons;
 
therefore, only fixed­effect model is applicable.
 
The following direct comparisons were statistically significant.

•	 There were more liver transplants with sulfamethoxazole plus
 
trimethoprim versus norfloxacin: HR 2.71 (95% CrI 1.10 to 7.59;
 
1 trial, 80 participants; low­certainty evidence).
 
•	 There were fewer liver transplants with rufloxacin versus
 
norfloxacin: there were 0/39 (0%) liver transplants in the
 
rufloxacin group compared to 8/40 (20%) in the norfloxacin
 
group (1 trial, 79 participants; low­certainty evidence).
 
There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant).
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•	 Sulfamethoxazole plus trimethoprim versus norfloxacin: HR
 
2.74 (95% CrI 1.12 to 7.08; low­certainty evidence). This was
 
consistent with that of the direct comparison.
 
There was no evidence of differences between the treatments in
 
the remaining comparisons in the network meta­analysis (Table
 
3). The sensitivity analysis indicated that the different scenarios
 
(best­worst and worst­best scenarios) for imputing missing data
 
indicated different interpretation of results; therefore, the results
 
have to be interpreted with caution.
 
Proportion with spontaneous bacterial peritonitis
 
None of the trials reported proportion with symptomatic
 
spontaneous bacterial peritonitis. Sixteen trials (1564 participants)
 




Trespi 1999; Bauer 2002; Alvarez 2005; Fernandez 2007; Terg 2008;
 
Lontos 2014; Tellez­Avila 2014; Assem 2016; Elfert 2016; Kimer 2017;
 
Praharaj 2017; Yim 2018). These trials compared seven treatments.
 
One trial was not connected to the network because it was the only
 
trial for the comparison and had zero events in one of the arms
 
(Singh 1995), and therefore was excluded from the network. All the
 
seven treatments were connected. Fifteen trials (1504 participants)
 
were included in the network.
 
There was evidence of inconsistency according to inconsistency
 
factor (one loop involving 'no active intervention', norfloxacin, and
 
rifaximin), and the 'between­design' variance 4.34 (95% CrI 0.29 to
 
21.57), but not by model fit. We did not attempt to exclude the
 
studies causing the inconsistency since the three interventions in
 
the inconsistent loop were the three main interventions compared
 
in this review; the definitions used for spontaneous bacterial
 
peritonitis development was similar in the trials, suggesting that
 
the differences across comparisons could not be explained by
 
the heterogeneity in the definitions used across comparisons.
 
Therefore, only the direct comparison results are presented.
 
In the direct comparison, the incidence of spontaneous bacterial
 
peritonitis was 0/30 in the sulfamethoxazole plus trimethoprim
 
group versus 4/30 in the no active intervention group (1 trial, 60
 
participants). The HR could not be estimated because of zero events
 
in the sulfamethoxazole plus trimethoprim group and the upper
 








•	 Rifaximin versus no active intervention: HR 7.80 (95% CrI 0.13 to
 
4647.11; 2 trials, 106 participants; very low­certainty evidence).
 
•	 Norfloxacin versus no active intervention: HR 0.16 (95% CrI 0.00
 
to 1.56; 3 trials, 255 participants; very low­certainty evidence).
 
•	 Ciprofloxacin versus no active intervention: HR 0.56 (95% CrI
 




•	 Norfloxacin versus rifaximin: HR 3.59 (95% CrI 0.46 to 33.18; 3
 
trials, 481 participants; very low­certainty evidence).
 
•	 Norfloxacin plus rifaximin versus rifaximin: HR 0.59 (95% CrI 0.11
 
to 2.51 ; 1 trial, 161 participants; very low­certainty evidence).
 
•	 Ciprofloxacin versus norfloxacin: HR 0.68 (95% CrI 0.12 to 3.49; 1
 
trial, 112 participants; very low­certainty evidence).
 
•	 Sulfamethoxazole plus trimethoprim versus norfloxacin: HR 1.48
 




•	 Norfloxacin plus rifaximin versus norfloxacin: HR 0.29 (95%
 




•	 Rufloxacin versus norfloxacin: HR 2.31 (95% CrI 0.88 to 6.70; 1
 
trial, 79 participants; very low­certainty evidence).
 
Number of decompensation episodes
 
Eight trials (1275 participants) reported number of other
 
decompensation events (Ginés  1990;  Madrid  2001;  Fernandez
 
2007;  Bass  2010;  Ali  2014;  Moreau 2015;  Nawaz 2015;  Assem
 
2016). From the information available in the trials, it was unclear
 
whether each participant developed only one decompensation
 
event. Therefore, we analysed this outcome as a count outcome.
 
These trials compared five treatments. All the trials were connected
 
to the network. There was no evidence of inconsistency according
 
to the 'between­design' variance: 1.49 (95% CrI 0.00 to 21.25),
 
inconsistency factor, or model fit. The fixed­effect model was used
 








•	 Rifaximin versus 'no active intervention': RaR 0.63 (95% CrI 0.48
 
to 0.82; 3 trials, 575 participants; low­certainty evidence).
 
•	 Norfloxacin plus neomycin versus 'no active intervention': RaR
 




There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 




In the network meta­analysis, the following comparisons were
 
statistically significant (Table 3).

•	 Rifaximin versus 'no active intervention': RaR 0.61 (95% CrI 0.46
 
to 0.80; low­certainty evidence).
 
•	 Norfloxacin plus neomycin versus 'no active intervention': RaR
 
0.06 (95% CrI 0.00 to 0.33; low­certainty evidence).
 
•	 Norfloxacin plus neomycin versus rifaximin: RaR 0.09 (95% CrI
 
0.00 to 0.55; low­certainty evidence).
 
•	 Norfloxacin plus neomycin versus norfloxacin: RaR 0.07 (95% CrI
 
0.00 to 0.43; low­certainty evidence).
 
There was no evidence of differences between the treatments in
 




Length of hospital stay
 
Two trials (139 participants) reported length of hospital stay
 
(Rolachon 1995; Bauer 2002). These trials compared four different
 
treatments. The trials were not connected by common treatments.
 
Therefore, only direct comparisons were performed. Only one trial
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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was included in each of the comparisons; therefore, we estimated
 
the effect estimates from a single trial for each comparison.
 
Ciprofloxacin had lower length of hospital stay versus 'no active
 
intervention' (MD –8.29 days, 95% CrI –11.09 to –5.50; 1 trial,
 
60 participants; low­certainty evidence). There was no evidence
 
of a difference between the treatments in the remaining direct
 
comparison between rufloxacin and norfloxacin (MD –0.70 days,
 
95% CrI –5.07 to 3.65; 1 trial, 79 participants; very low­certainty
 
evidence). There was no imputation of mean or standard deviation;
 
therefore, sensitivity analysis was not applicable.
 
Number of days of lost work
 








Data were sufficient to perform the following subgroup analyses:
 
ascites with low protein; primary prophylaxis; and duration of
 
follow­up (short­term versus medium term). There was insufficient
 
data for the remaining subgroup analyses or only one subgroup
 
was represented in the analyses. There were no subgroup
 
differences for any of the outcomes where there was at least
 
two different subgroups represented in the analyses (all­cause
 
mortality, number of serious adverse events per participant, or
 
other decompensation events). There was no convergence for
 
model fit procedures of the subgroup analysis for proportion of
 
any adverse events, probably because of the complex model with
 
sparse data (only three trials with three connected treatments)
 
and liver transplantation (only three trials with four connected
 
treatments). Only direct comparisons were performed for number
 
of 'any adverse events' per participant and spontaneous bacterial
 
peritonitis; the number of studies included in each direct
 
comparison was insufficient to perform the subgroup analyses.
 
Assessment of reporting biases
 
Since there was no meaningful way in which to rank these studies
 
(i.e. there was no specific change in the risk of bias in the
 
studies, sample size, or the control group used over time), we
 
were unable to perform the comparison­adjusted funnel plot. Many
 
trials did not report outcomes such as mortality, adverse events,
 
or decompensation events, outcomes that are likely to have been
 




Summary of main results
 
We performed a systematic review and network meta­analysis of
 
all the antibiotic prophylaxis for spontaneous bacterial peritonitis
 
in people with decompensated liver cirrhosis. We included 29 trials
 
including 3896 participants. The trials compared 10 interventions.
 
A total of 23 trials including 2587 participants were included for one
 




2005; Fernandez 2007; Terg 2008; Bass 2010; Ali 2014; Lontos 2014;
 
Tellez­Avila 2014;  Baik  2015;  Moreau 2015;  Mostafa 2015;  Nawaz
 




Overall, 15% of the trial participants died within one year. There
 
was no evidence of a difference in mortality or serious adverse
 
events in any of the direct comparisons or network meta­analysis.
 
However, the CrIs were wide, and clinically important differences
 
in mortality or serious adverse events could not be ruled out.
 
The number of any adverse events per participant was fewer with
 
norfloxacin and sulfamethoxazole plus trimethoprim than with
 
no active intervention. There were some comparisons in which
 
there were differences in any adverse events per participant; liver
 
transplantation; spontaneous bacterial peritonitis development;
 
other decompensation events; and length of hospital stay. One
 
would expect some correlation between outcomes (i.e. if the
 
intervention was effective, it is expected to be effective across
 
these outcomes). This was not the case. The possible reasons for
 
this include sparse data and selective reporting bias. Since these
 
outcomes are likely to be measured routinely in a clinical trial of
 
this nature, but were not reported in many of the trials, one has
 
to suspect selective outcome reporting bias strongly (i.e. the trial
 
authors were reporting outcomes based on the direction of the
 
results). This makes the results unreliable. Therefore, one cannot
 




In terms of the design of a future trial to answer the research
 
question, the median control group (no active intervention)
 
mortality within 12 months was 18.4%. The sample size required
 
to detect a relative risk reduction of 20% in the experimental
 
group, type I error of 5%, and type II error of 20% was 3202
 
participants. Given that approximately 20% of people with liver
 
cirrhosis develop ascites, the conduct of this trial is feasible.
 
Development of spontaneous bacterial peritonitis may not be
 
a good primary outcome in such a trial since the median
 
control group (no active intervention) was 14.0%, which was less
 
than the mortality. Since similar trials reported development of
 
spontaneous bacterial peritonitis, it appears that people with
 
ascites were dying of other causes besides spontaneous bacterial
 
peritonitis. In the trials that reported the causes of mortality,
 
the cause of death was due to spontaneous bacterial peritonitis
 
and other decompensation events. There were approximately 46
 
other decompensation events per 100 participants (in addition to
 
spontaneous bacterial peritonitis development) in the 'no active
 
intervention' group (i.e. about 60 events in total in the 'no active
 
intervention group'). In addition to causing death, decompensation
 
usually results in hospital admissions and significant costs.
 
Therefore, 'any decompensation event' is another possible primary
 
outcome. Assuming that the variance was equal to the mean in an
 
ordinary Poisson distribution commonly used to analyse recurrent
 
events (that happen independently, although this is a questionable
 
assumption), a 20% relative risk reduction in the experimental
 
group, type I error of 5%, and type II error of 20%, the sample
 




In terms of the interventions to be compared, the American
 
Association For the Study of Liver Diseases (AASLD) and the EASL
 
both suggest that people with ascites with low protein or those who
 
had previous episodes of spontaneous bacterial peritonitis receive
 
norfloxacin as antibiotic prophylaxis. Despite the uncertainty in its
 
effectiveness, it could be one of the interventions in a future trial, as
 
it might prove to be difficult to recruit participants into a trial with
 
'no active intervention' because of the recommendations in these
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guidelines. However, this might be possible in people with cirrhosis
 
at low risk of spontaneous bacterial peritonitis.
 
Rifaximin is potentially effective in preventing recurrent hepatic
 
encephalopathy (Bass  2010). Therefore, rifaximin can be one
 
of the other interventions compared. While there is no high­

certainty evidence indicating that these interventions are better
 
than no antibiotics for major outcomes such as mortality
 
and the trials included for different outcomes were different
 
suggesting the possibility of selective reporting bias, it is unclear
 
whether patients will accept to be randomised to 'no active
 
intervention' ('no intervention' or 'placebo') and clinicians will
 
randomise participants in a trial with 'no active intervention' as
 
one of the arms. Therefore, further involvement of patients and
 




Overall completeness and applicability of evidence
 
The trials included a wide variety of people with cirrhosis having
 
ascites with low protein or previous history of spontaneous
 
bacterial peritonitis. However, it was unclear whether any of the
 
trials included participants with no previous history of spontaneous
 
bacterial peritonitis and had normal protein in their ascites.
 
Therefore, the findings of this review are applicable only in people
 




There did not seem to be any restrictions based on the aetiology
 
or the presence of other features of decompensation in the
 
trials that provided this information. Therefore, the results of
 
the study are applicable in all people with cirrhosis having
 
ascites with low protein or previous history of spontaneous
 
bacterial peritonitis. We excluded trials in which participants had
 
undergone liver transplantation. Therefore, the findings of this
 
review are not applicable in people with ascites secondary to liver
 
decompensation after liver transplantation.
 
Quality of the evidence
 
The overall certainty (quality) of evidence was low or very low.
 
One of the main reasons for the very low certainty of evidence
 
was the unclear or high risk of bias in many of the trials. It is
 
possible to perform trials of low risk of bias in the field. To perform
 
a low risk of bias trial, randomisation can be performed using
 
standard methods, for example, web­based central randomisation;
 
blinding of parties involved can be achieved by using double­

placebo design even if two interventions at different frequencies
 
are given (i.e. a placebo for intervention and a placebo for control);
 
an intention­to­treat analysis can be performed; and a protocol can
 
be published prior to recruitment. None of these have any major
 




Another major reason for very low certainty of evidence was
 
imprecision: the trials had small sample sizes and the CrIs
 
overlapped clinically significant benefits and clinically significant
 
harms for most comparisons. Therefore, future trials should
 
be adequately powered with sample sizes as described in the
 
Summary of main results section.
 
We used clinical outcomes; therefore, there is no issue of
 
indirectness due to outcomes. There was no suggestion that
 
the potential effect modifiers were systematically different
 
across comparisons (i.e. there was no concern about transitivity
 
assumption). There was no evidence of inconsistency in most of
 
the outcomes (except number of 'any adverse events'). However,
 
one cannot rule out inconsistency ('incoherence' according to
 
GRADE terminology). There was no meaningful way to rank these
 
studies (i.e. there was no specific change in the risk of bias in the
 
studies, sample size, or the control group used over time); we have
 
completed a thorough search for studies on effectiveness. However,
 
different sets of trials were included for different outcomes. It
 
is extremely likely that trials in this group of patients measured
 
adverse events, decompensation events, and liver transplantation
 
during the follow­up period; nevertheless, many trials did not
 
report these outcomes suggesting reporting bias.
 
Potential biases in the review process
 
We selected a range of databases to search without using any
 
language restrictions and conducted the network meta­analysis
 
where appropriate according to NICE DSU guidance. In addition,
 
we analysed data using the fixed­effect model and random­

effects model, and assessed and reported inconsistency whenever
 
possible. These are the strengths of the review process.
 
We excluded studies that compared variations in duration or dose
 
in the different interventions. Hence, this review does not provide
 
information on whether one variation is better than another.
 
Another major limitation of this review was the paucity of data: the
 




All of the network meta­analyses included only sparse data from
 
trials, most of which were at high risk of bias. However, the potential
 
effect modifiers in the trials that reported them were broadly
 
similar across comparisons. The results of direct comparisons and
 
indirect comparisons were similar for the outcomes where we could
 
assess this. Therefore, the concern about transitivity assumption
 
was low. However, lack of transitivity could not be ruled out.
 
We included only randomised clinical trials which are known to
 
focus mostly on benefits and do not collect and report harms
 
in a detailed manner. Therefore, it is possible that we missed
 
a large number of non­randomised studies addressing reporting
 
of harms. A significant effort is required to identify the non­

randomised studies and assess the risk of bias in those studies.
 
Since it is possible to conduct future studies powered on mortality
 
(which is likely to be sufficient to identify any clinically meaningful
 
differences in health­related quality of life), a systematic review on
 
adverse events appears to be unnecessary. This is because of the
 
uncertainty in the benefits of different treatments; in addition, the
 
patients are likely to give more importance to mortality and quality
 
of life than adverse events.
 




This is the first network meta­analysis on the topic. There have
 
been several systematic reviews on antibiotic prophylaxis in people
 
with cirrhosis having ascites with low protein or previous history
 




Cohen 2009 pooled all antibiotic prophylaxis versus no prophylaxis.
 
They found that the trials, which were at high risk of bias, found
 
lower mortality and incidence of spontaneous bacterial peritonitis
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with antibiotic prophylaxis, but they highlighted that there is
 
uncertainty about the effectiveness because of the risk of bias in the
 
trials. We have treated different antibiotic prophylaxes as different
 
interventions in this review and used Bayesian analysis (which
 
is more conservative than frequentist meta­analysis (unpublished
 
data by the Cochrane Methods Group), which may be the reason for
 
finding that there was no evidence of difference in mortality.
 
The other systematic reviews compared rifaximin versus other
 
antibiotics or 'no active treatment' (Goel 2017; Kamal 2017; Sidhu
 
2017). All three systematic reviews included randomised and
 
non­randomised studies and found that rifaximin may be more
 
effective in preventing spontaneous bacterial peritonitis than other
 
antibiotics and 'no active treatment'. Inclusion of non­randomised
 
studies and pooling all systemic antibiotics into one group may be
 








Based on very low­certainty evidence, there is considerable
 
uncertainty about whether antibiotic prophylaxis is beneficial and
 
if beneficial, which antibiotic prophylaxis is most beneficial in
 






Further well­designed randomised clinical trials are necessary.
 








Participants: people with liver cirrhosis and ascites.
 
Intervention: rifaximin, norfloxacin, or a combination of the two.
 
Control: no active intervention (if it is feasible to include this as one
 
of the control groups). No active intervention may be as feasible as
 








Secondary outcomes: health­related quality of life;
 
decompensation events; adverse events; incidence of spontaneous
 
bacterial peritonitis; and resource utilisation measures including
 
length of hospital stay.
 
Minimum length of follow­up: one year.
 
Sample size: for a simple two­arm parallel randomised clinical
 
trial, the sample size required to detect a relative risk reduction of
 
20% in the experimental group from the control group proportion
 
of 18.4% mortality, type I error of 5%, and type II error of
 
20%, 3202 participants are required. For participants at low risk
 
of spontaneous bacterial peritonitis, there is no information to
 
calculate the sample size from this systematic review. A feasibility
 
randomised clinical trial can provide the potential effect size and
 
allow sample size calculations.
 
Other aspects: trials need to be conducted and reported according
 
to the SPIRIT (Standard Protocol Items: Recommendations for
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Abdel Motelleb 2016  (Continued)
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
 
Interventions Participants randomly assigned to 3 groups. 
Group 1: norfloxacin + rifaximin (n = not stated) 
Further details: norfloxacin + rifaximin (no further details) for 6 months 
Group 2: norfloxacin (n = not stated) 
Further details: norfloxacin (no further details) for 6 months 
Group 3: rifaximin (n = not stated) 
Further details: rifaximin (no further details) for 6 months 
No information on the number of participants in each group 
Outcomes None of the outcomes of interest were reported. 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 
Blinding of participants Unclear risk Quote: "Single­blind." 
and personnel (perfor­
mance bias)  Comment: further information not available 
All outcomes 
Blinding of outcome as­ Unclear risk Quote: "Single­blind." 
sessment (detection bias) 
All outcomes Comment: further information not available 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
Other bias Low risk Comment: no other bias noted 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 














         
     
               
         
                       
         
       
         
         
                           
             
         
               
                   
 
                             


















Postrandomisation dropouts: not stated
 
Revised sample size: 126
 






variceal bleeding): 126 (100%)
 
Ascites with low protein: not stated
 






Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 2 (1.6%)
 








• hypersensitivity to rifamycin and its products
 






Interventions Participants randomly assigned to 2 groups. 
Group 1: rifaximin (n = 63) 
Further details: rifaximin 550 mg BD for 6 months or until recurrence of hepatorenal syndrome 
Group 2: no active intervention (n = 63) 
Further details: placebo for 6 months 
Outcomes Outcomes reported: all­cause mortality; number of other decompensation events 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
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Library Better health. Cochrane Database of Systematic Reviews
 
Ali 2014  (Continued) 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Allocation concealment 
(selection bias) 





Low risk Quote: "Triple blind randomized placebo­controlled trial… The patients, the 
investigator and the statistician did not know which patients were receiving 




Low risk Quote: "Triple blind randomized placebo­controlled trial… The patients, the 
investigator and the statistician did not know which patients were receiving 




Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report adverse events 
adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 57
 






variceal bleeding): not stated
 






Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 37 (64.9%)
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Alvarez 2005  (Continued) 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Interventions Participants randomly assigned to 2 groups. 
Group 1: sulfamethoxazole + trimethoprim (n = 25) 
Further details: sulfamethoxazole 160 mg + trimethoprim 800 mg daily for 5 days a week (duration not 
stated, but probably until follow­up 
Group 2: norfloxacin (n = 32) 
Further details: norfloxacin 400 mg daily for 5 days a week (duration not stated, but probably until fol­
low­up) 
Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with 
spontaneous bacterial peritonitis (as per definition) 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: information not available 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: protocol not available, but authors reported mortality and adverse 
porting bias) events adequately. 
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Postrandomisation dropouts: not stated
 
Revised sample size: 239
 






variceal bleeding): 56 (23.4%)
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 17 (7.1%)
 














• known hypersensitivity to planned drugs
 
Interventions	 Participants randomly assigned to 3 groups.
 
Group 1: rifaximin + norfloxacin (n = 79)
 




Group 2: norfloxacin (n = 78)
 
Further details: norfloxacin 400 mg OD orally for 6 months
 
Group 3: rifaximin (n = 82)
 
Further details: rifaximin 550 mg BD orally for 6 months
 
Outcomes	 Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with
 








Bias	 Authors' judgement Support for judgement
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Assem 2016  (Continued) 
Allocation concealment 
(selection bias) 














Unclear risk Comment: appeared some people were excluded from some outcomes, but in­
formation not clear. 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 65
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 
Primary prophylaxis: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 




• people with advanced cirrhosis (no further details on how advanced cirrhosis was defined)
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Baik 2015  (Continued) 
Interventions Participants randomly assigned to 2 groups. 
Group 1: rifaximin (n = 17) 
Further details: rifaximin 1200 mg/day for 3 months 
Group 2: no active intervention (n = 48) 
Further details: no treatment 
Additional details: both groups received propranolol 
Outcomes Outcomes reported: number of any adverse events per participant 
Follow­up (months): 3 
Notes Attempted to contact authors in November 2018, but received no replies 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: information not available 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report adverse events 
porting bias) adequately. 





Participants	 Country: USA and Russia
 




Postrandomisation dropouts: 2 (0.4%)
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Revised sample size: 516
 
Reasons for postrandomisation dropouts: not stated
 






variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 231 (44.8%)
 










Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: rifaximin (n = 422)
 
Further details: rifaximin 40–160 mg (immediate release and soluble solid dispersion) for 24 weeks
 
Group 2: no active intervention (n = 94)
 
Further details: placebo for 24 weeks
 




Notes Trial name/trial registry number: NCT01904409
 




Bias	 Authors' judgement Support for judgement
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Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report adverse events 
adequately. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 299
 






variceal bleeding): 299 (100%)
 
Ascites with low protein: not stated
 
Primary prophylaxis: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
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Bass 2010  (Continued) 
Interventions Participants randomly assigned to 2 groups. 
Group 1: rifaximin (n = 140) 
Further details: rifaximin 550 mg BD for 6 months or until recurrence of hepatorenal syndrome 
Group 2: no active intervention (n = 159) 
Further details: placebo for 6 months 
Outcomes Outcomes reported: all­cause mortality; number of serious adverse events per participant; proportion 
of people with any adverse events; number of any adverse events per participant; number of other de­
compensation events. 
Follow­up (months): 6 
Notes Trial name/trial registry number: NCT00298038 
Attempted to contact authors in November 2018, but received no replies 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Low risk Quote: "Double­blind placebo­controlled trial." 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: no postrandomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: protocol not available, but authors reported mortality and adverse 
porting bias) events adequately. 
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Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 79
 






variceal bleeding): 52 (65.8%)
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 3 (3.8%)
 












•	 known or suspected hypersensitivity to quinolones
 




Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: rufloxacin (n = 39)
 




Group 2: norfloxacin (n = 40)
 
Further details: norfloxacin 400 mg OD orally (duration not stated, but appeared continuous)
 
Outcomes	 Outcomes reported: all­cause mortality; number of any adverse events per participant; liver transplan­









Bias	 Authors' judgement Support for judgement
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Low risk Comment: no postrandomisation dropouts 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report adverse events 
adequately. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 262
 






variceal bleeding): not stated
 




Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 












• recent intake of quinolones in the last 6 weeks
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Elfert 2016  (Continued) 
• HIV infection
• hepatic encephalopathy
• pregnant and lactating women 
Interventions Participants randomly assigned to 2 groups. 
Group 1: norfloxacin (n = 131) 
Further details: norfloxacin 400 mg daily for 6 months 
Group 2: rifaximin (n = 131) 
Further details: rifaximin 400 mg TDS for 6 months 
Outcomes Outcomes reported: all­cause mortality; proportion of people with serious adverse events; number of 
serious adverse events per participant; proportion of people with any adverse events; proportion with 
spontaneous bacterial peritonitis (as per definition). 
Follow­up (months): 6 
Notes Trial name/trial registry number: NCT02120196 
Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "Eligible patients were randomized using a computer random number 
tion (selection bias) generator." 
Allocation concealment Low risk Quote: "Sequentially numbered, opaque, sealed envelopes." 
(selection bias) 




Blinding of outcome as­ High risk Quote: "Open­label." 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: no postrandomisation dropouts 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: protocol not available, but authors reported mortality and adverse 
porting bias) events adequately. 
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Postrandomisation dropouts: 6 (8.1%)
 
Revised sample size: 68
 
Reasons for postrandomisation dropouts: not stated
 






variceal bleeding): 24 (35.3%)
 






Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 5 (7.4%)
 














Interventions Participants randomly assigned to 2 groups. 
Group 1: norfloxacin (n = 35) 
Further details: norfloxacin 400 mg daily (duration not stated, but probably to end of follow­up) 
Group 2: no active intervention (n = 33) 
Further details: placebo 




Notes Trial name/trial registry number: NCT00359853 
Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Fernandez 2007  (Continued) 
Random sequence genera­
tion (selection bias) 


















Unclear risk Comment: there were postrandomisation dropouts; unclear whether these 
could be related to treatment. 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 80
 






variceal bleeding): not stated
 






Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 34 (42.5%)
 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
 
Interventions Participants randomly assigned to 2 groups.
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Group 1: norfloxacin (n = 40)
 
Further details: norfloxacin 400 mg daily (duration not stated, but probably to end of follow­up)
 




Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with 
spontaneous bacterial peritonitis (as per definition); number of other decompensation events. 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Allocation concealment 
(selection bias) 





Low risk Quote: "Double­blind, multicenter, placebo­controlled study… Each patient's 




Low risk Quote: "Double­blind, multicenter, placebo­controlled study… Each patient's 




Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 107
 
Mean age (years): 55
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variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 4 (3.7%)
 






• hepatocellular carcinoma or other life­threatening disease
 
Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: norfloxacin (n = 53)
 
Further details: norfloxacin 400 mg daily (duration not stated, but probably to end of follow­up)
 














Bias	 Authors' judgement Support for judgement
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Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 80
 






variceal bleeding): 11 (13.8%)
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 6 (7.5%)
 
















Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: rifaximin (n = 40)
 
Further details: rifaximin 550 mg BD for 3 months
 




Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 








       
             







                     









         
     
 
                             






Library Better health. Cochrane Database of Systematic Reviews
 
Ibrahim 2017  (Continued) 
Outcomes None of the outcomes of interest were reported. 
Follow­up (months): 3 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Allocation concealment 
(selection bias) 













Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report mortality or ad­
verse events, which are expected to be reported in such trials. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 54
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 
Primary prophylaxis: not stated
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Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 2 (3.7%)
 
Other causes for cirrhosis: 4 (7.4%)
 














• antibiotic treatment 14 days prior to inclusion
 












Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: rifaximin (n = 36)
 
Further details: rifaximin 550 mg BD for 4 weeks
 




Outcomes	 Outcomes reported: all­cause mortality; number of serious adverse events per participant; number of
 






Notes Trial name/trial registry number: NCT01769040
 




Bias	 Authors' judgement Support for judgement
 








Blinding of participants Low risk Quote: "Double­blind, randomized, and placebo­controlled trial… All patients
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Low risk Quote: "Double­blind, randomized, and placebo­controlled trial… All patients 




Low risk Comment: no postrandomisation dropouts 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 280
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 














• altered conscious level due to drug poisoning
 
• hypersensitive to neomycin or ciprofloxacin
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Latif 2016  (Continued) 
• comorbid condition such as glomerulonephritis, renal failure, and congestive heart failure 
• people already receiving oral antibiotics on regular basis 
• contraindication for use of aminoglycosides and fluoroquinolones 
Interventions Participants randomly assigned to 2 groups. 
Group 1: neomycin (n = not stated) 
Further details: neomycin (no further details on dose or duration) 
Group 2: ciprofloxacin (n = not stated) 
Further details: ciprofloxacin (no further details on dose or duration) 
Additional details: no information on the number of participants in each group. 
Outcomes None of the outcomes of interest were reported. 
Follow­up (months): 1 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: information not available 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
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Postrandomisation dropouts: not stated
 
Revised sample size: 80
 






variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 17 (21.3%)
 




• allergies to sulphur­containing drugs or quinolones
 
• documented failure of either study drug in the past while on prophylaxis
 
















Interventions Participants randomly assigned to 2 groups. 
Group 1: sulfamethoxazole + trimethoprim (n = 40) 
Further details: sulfamethoxazole 160 mg + trimethoprim 800 mg daily (duration not stated, but proba­
bly until follow­up) 
Group 2: norfloxacin (n = 40) 
Further details: norfloxacin 400 mg daily (duration not stated, but probably until follow­up) 




Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Lontos 2014  (Continued) 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 


















Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 22
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 






Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 2 (9.1%)
 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 








       
   
                   
         
             
                           
     
             
                     
           





                     
 
                             




























• treated with lactulose, antibiotics, or prokinetic drugs during past 30 days
 
Interventions Participants randomly assigned to 2 groups. 
Group 1: norfloxacin + neomycin (n = 12) 
Further details: norfloxacin 400 mg BD alternating with neomycin 500 mg TDS, alternating every 15 
days for 6 months 
Group 2: no active intervention (n = 10) 
Further details: placebo 
Additional details: another group which received cisapride was excluded from the analysis 
Outcomes Outcomes reported: number of other decompensation events 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: placebo used but no information about blinding provided. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 



















         
     
               
         
                       
         
         
               
         
               
             
                   
   
 
                             






















Postrandomisation dropouts: not stated
 
Revised sample size: 60
 






variceal bleeding): 60 (100%)
 
Ascites with low protein: not stated
 






Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 1 (1.7%)
 






Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: neomycin (n = 30)
 
Further details: neomycin 1 g TDS for 6 months
 
Group 2: rifaximin (n = 30)
 
Further details: rifaximin 400 mg TDS for 6 months
 








Bias	 Authors' judgement Support for judgement
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 








       
                 
                   
                           
                 
                         
 
                 
                   
                           
                 
                         
 
           
           
     






       
     
     
       
   
     
         
     
   
                             











Low risk Quote: "Patients were randomly assigned, following a predetermined com­
puter­generated list supplied by Alfa Wassermann (Bologna, Italy), either to ri­
faximin 400 mg three times daily or neomycin 1 g three times daily… The two 
drugs were supplied by Alfa Wassermann, as identical tablets, indistinguish­




Low risk Quote: "Patients were randomly assigned, following a predetermined com­
puter­generated list supplied by Alfa Wassermann (Bologna, Italy), either to ri­
faximin 400 mg three times daily or neomycin 1 g three times daily… The two 
drugs were supplied by Alfa Wassermann, as identical tablets, indistinguish­














Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Protocol not available, and authors did not report the outcomes assessed ade­
quately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 291
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
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Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: 68 (23.4%)
 






Interventions Participants randomly assigned to 2 groups. 
Group 1: norfloxacin (n = 144) 
Further details: norfloxacin 400 mg daily for 6 months 
Group 2: no active intervention (n = 147) 
Further details: placebo 
Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; number of oth­
er decompensation events 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Low risk Quote: "Double­blind, placebo­controlled." 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
Other bias Low risk Comment: no other bias noted 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 














         
               
         
                       
       
   
         
         
                                   
         
               
                 
             
                   
   
   
                             


















Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 20
 






variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 0 (0%)
 
Other causes for cirrhosis: not stated
 










• allergy to quinolones
 
Interventions Participants randomly assigned to 2 groups.
 
Group 1: sparfloxacin (n = 10)
 




Group 2: ciprofloxacin (n = 10)
 
Further details: ciprofloxacin 750 mg/week orally for 6 months
 
Additional details: 2 other groups that received pentoxyphylline were excluded
 








Bias Authors' judgement Support for judgement
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Mostafa 2014  (Continued) 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Allocation concealment 
(selection bias) 





Unclear risk Quote: "Randomized, blind, and controlled study." 




Unclear risk Quote: "Randomized, blind, and controlled study" 




Low risk Comment: no postrandomisation dropouts 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report the outcomes as­
sessed adequately. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 70
 






variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 0 (0%)
 
Other causes for cirrhosis: 0 (0%)
 




Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Mostafa 2015  (Continued) 
• active gastrointestinal bleeding
• encephalopathy (> grade 2) 
• hepatocellular carcinoma or other malignancies
• allergy to medications used 
Interventions Participants randomly assigned to 2 groups. 
Group 1: norfloxacin (n = 30) 
Further details: norfloxacin 400 mg daily for 6 months 
Group 2: rifaximin (n = 40) 
Further details: rifaximin 800 mg daily for 6 months 
Additional details: the information in table 1 was incorrect, so no details entered. 
Outcomes Outcomes reported: proportion of people with serious adverse events; number of serious adverse 
events per participant; proportion of people with any adverse events 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 
Blinding of participants Unclear risk Quote: "Single­blind" 
and personnel (perfor­
mance bias)  Comment: further information not available. 
All outcomes 
Blinding of outcome as­ Unclear risk Quote: "Single­blind" 
sessment (detection bias) 
All outcomes Comment: further information not available. 
Incomplete outcome data Unclear risk Comment: unclear whether participants were excluded after randomisation. 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
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Postrandomisation dropouts: not stated
 
Revised sample size: 150
 






variceal bleeding): 150 (100%)
 
Ascites with low protein: not stated
 
Primary prophylaxis: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 






Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: rifaximin (n = 75)
 
Further details: rifaximin 550 mg BD for 6 months
 












Bias	 Authors' judgement Support for judgement
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Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report the outcomes as­
sessed adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 59
 






variceal bleeding): not stated
 




Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
 
Interventions Participants randomly assigned to 2 groups.
 
Group 1: norfloxacin (n = 33)
 
Further details: norfloxacin 400 mg daily for 6 months
 
Group 2: rifaximin (n = 26)
 
Further details: rifaximin 550 mg BD for 6 months
 
Additional details: another 58 participants with high Child­Turcotte­Pugh score were excluded as it was
 
unclear whether these participants had clinical features of decompensated liver disease.
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Praharaj 2017  (Continued) 
Outcomes Outcomes reported: proportion with spontaneous bacterial peritonitis (as per definition) 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Allocation concealment 
(selection bias) 













Unclear risk Comment: information not available 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report the outcomes as­
sessed adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 60
 






variceal bleeding): not stated
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Rolachon 1995  (Continued) 
Alcohol­related cirrhosis: 55 (91.7%) 
Viral­related cirrhosis: 1 (1.7%) 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 2 (3.3%) 
Other causes for cirrhosis: 2 (3.3%) 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Interventions Participants randomly assigned to 2 groups. 
Group 1: ciprofloxacin (n = 28) 
Further details: ciprofloxacin 750 mg/week orally for 6 months 
Group 2: no active intervention (n = 32) 
Further details: placebo 
Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with 
spontaneous bacterial peritonitis (as per definition); length of hospital stay 
Follow­up (months): 6 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Low risk Quote: "Double­blind … placebo" 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
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Singh 1995  (Continued) 
Participants Country: USA 
Period of recruitment: not stated 
Number randomised: 60 
Postrandomisation dropouts: 0 (0%) 
Revised sample size: 60 
Mean age (years): 45 
Females: not stated 
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or 
variceal bleeding): not stated 




Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: 5 (8.3%) 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Exclusion criteria: 
• allergy to sulfonamides 
• renal failure
• active infections 
Interventions Participants randomly assigned to 2 groups. 
Group 1: sulfamethoxazole + trimethoprim (n = 30) 
Further details: sulfamethoxazole 160 mg + trimethoprim 800 mg daily (duration not stated, but proba­
bly until follow­up) 
Group 2: no active intervention (n = 30) 
Further details: no treatment 
Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with 
spontaneous bacterial peritonitis (as per definition). 
Follow­up (months): 3 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: information not available 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 












       










         
               
         
                       
         
   
                             
























Low risk Comment: no postrandomisation dropouts 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 95
 






variceal bleeding): not stated
 








Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 0 (0%)
 
Other causes for cirrhosis: 17 (17.9%)
 






• antibiotics within the last 30 days
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
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Tellez­Avila 2014  (Continued) 
• pregnancy




• allergy to fluoroquinolones 
• bacterial infection at the time of enrolment 
Interventions Participants randomly assigned to 2 groups. 
Group 1: ciprofloxacin (n = 49) 
Further details: ciprofloxacin 500 mg/day for 1 month 
Group 2: no active intervention (n = 46) 
Further details: placebo 
Outcomes Outcomes reported: all­cause mortality; number of any adverse events per participant; proportion with 
spontaneous bacterial peritonitis (as per definition) 
Follow­up (months): 4 
Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Low risk Quote: "A random allocation sequence was generated and kept in a sealed en­
(selection bias) velope." 




Blinding of outcome as­ Low risk Quote: "Randomized, double­blind placebo­controlled clinical trial." 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: no postrandomisation dropouts 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: protocol not available, but authors reported mortality and adverse 
porting bias) events adequately. 
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Postrandomisation dropouts: 0 (0%)
 
Revised sample size: 100
 






variceal bleeding): not stated
 




Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 




















Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: ciprofloxacin (n = 50)
 
Further details: ciprofloxacin 500 mg/day (duration not stated – probably until end of follow­up)
 










Notes Trial name/trial registry number: CCT­NAPN­16065
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Terg 2008  (Continued) 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "Randomization was performed with sealed and consecutively num­




Low risk Quote: "Randomization was performed with sealed and consecutively num­
















Low risk Comment: no postrandomisation dropouts 
Selective reporting (re­
porting bias) 
Low risk Comment: protocol not available, but authors reported mortality and adverse 
events adequately. 











Postrandomisation dropouts: not stated
 
Revised sample size: 52
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 






Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): 0 (0%)
 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 








       
         
                       
         
         
                               
             













                             










Other causes for cirrhosis: 0 (0%)
 






Interventions Participants randomly assigned to 2 groups. 
Group 1: rifaximin (n = 27) 
Further details: rifaximin 400 mg BD for 1 week/month (duration not stated, probably until the end of 
the follow­up period) 




Notes Attempted to contact authors in November 2018, but received no replies. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: information not available 
tion (selection bias) 
Allocation concealment Unclear risk Comment: information not available 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: information not available 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: information not available 
(attrition bias) 
All outcomes 
Selective reporting (re­ High risk Comment: protocol not available, and authors did not report the outcomes as­
porting bias) sessed adequately. 
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Postrandomisation dropouts: 12 (9.7%)
 
Revised sample size: 112
 
Reasons for postrandomisation dropouts: not stated
 






variceal bleeding): not stated
 
Ascites with low protein: not stated
 
Primary prophylaxis: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis (e.g. PSC, PBC, AIH): not stated
 
Other causes for cirrhosis: not stated
 








• hepatic encephalopathy > stage 2
 






• women at child­bearing age unwilling to use effective measures for contraception
 
• pregnant or breast­feeding women
 
Interventions	 Participants randomly assigned to 2 groups.
 
Group 1: ciprofloxacin (n = 57)
 
Further details: ciprofloxacin 750 mg weekly for 12 months
 
Group 2: norfloxacin (n = 55)
 
Further details: norfloxacin 400 mg daily for 12 months
 
Additional details: none of baseline characteristics were extracted as the outcomes were presented for
 
55 vs 57 participants, but the baseline characteristics were described for 62 participants in each group.
 






Notes Trial name/trial registry number: NCT01542801
 
Attempted to contact authors in November 2018, but received no replies.
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Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "The randomization table was generated by a statistician (SSK) using 
the nQuery Advisor program." 
Allocation concealment 
(selection bias) 













Unclear risk Comment: there were postrandomisation dropouts and it was unclear whether 
these were related to outcomes. 
Selective reporting (re­
porting bias) 
High risk Comment: protocol not available, and authors did not report the outcomes as­
sessed adequately. 
Other bias Low risk Comment: no other bias noted 
AIH: autoimmune hepatitis; BD: twice daily; n: number of participants; OD: once daily; PBC: primary biliary cirrhosis; PSC: primary
 
sclerosing cholangitis; TDS: three times daily.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion 
Anonymous 1971 Not a randomised clinical trial 
Anonymous 2006 Not a randomised clinical trial 
Assy 2005 Not a randomised clinical trial 
Bajaj 2012 Not a randomised clinical trial 
Bendtsen 2005 Not a randomised clinical trial 
Boccardi 1974 Not a randomised clinical trial 
Bode 1997 Not all participants had liver cirrhosis. 
Gerbes 1997 Not a randomised clinical trial 
Gines 1998 Not a randomised clinical trial 
Gupta 2013 Not all participants had decompensated liver cirrhosis. 
Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta­analysis (Review)
 








       
   
       
       
                             
                           
             
         
         
         
       
       
       
 
             
 
           
       
 





                             






Library Better health. Cochrane Database of Systematic Reviews
 
Reason for exclusion Study
 
Henrion 1992 Not a randomised clinical trial 
Jalan 2010 Not a randomised clinical trial 
Kemp 2009 Cross­over trial with short duration of treatment with no information on the outcomes prior to 
cross­over. 
Kumar 2014 Participants received a drug that is known to affect immune system; therefore, the effect estimates 
obtained were not relevant to the research question. 
Lata 2005 Short­term antibiotics for upper gastrointestinal bleeding 
Novella 1997 Comparison of 2 different regimens of the same drug 
Pateron 1992 Short­term antibiotics for upper gastrointestinal bleeding 
Rimola 1985 Short­term antibiotics for upper gastrointestinal bleeding 
Schubert 1991 Not a randomised clinical trial 
Siddique 2010 Not a randomised clinical trial 
Vibert 2008 Not a randomised clinical trial 







Interventions Group 1: norfloxacin 400 mg once daily 
Group 2: placebo once daily 
Outcomes Mortality, spontaneous bacterial peritonitis, other clinically significant infections, duration of un­
scheduled cirrhosis­associated hospitalisation within 12 months 
Starting date February 2014 
Contact information Dr Marcus Casper (Email: markus.casper@uks.eu) 
Notes German Clinical Trials Register DRKS00005616; EU Clinical Trials Register EudraCT 2013­001626­26 
A D D I T I O N A L  T A B L E S
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Table 1. Characteristics of included studies and potential effect modifiers (arranged by comparison)
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3601722.
 
Table 2. Model fit
 




All­cause mortality at maximal follow­up
 
Dbar 152.6 152.1 150.5
 
DIC 174.4 175.9 176.2
 
pD 21.8 23.81 25.75
 
Proportion of people with one or more serious adverse events
 
Dbar 152.6 152 —
 
DIC 174.4 175.7 —
 
pD 21.8 23.75 —
 
Number of serious adverse events per participant
 
Dbar 18.46 18.41 —
 
DIC 21.42 21.32 —
 




Dbar 33.46 29.75 —
 
DIC 38.49 35.41 —
 




Dbar 27.87 152 —
 
DIC 33.8 175.7 —
 




Dbar 150.1 121.8 121.9
 
DIC 170.6 149.6 147
 
pD 20.49 27.78 25.1
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Table 2. Model fit  (Continued)
 
Number of decompensation episodes
 
Dbar 95.85 95.75 92.91 
DIC 107.7 107.5 108.3 
pD 11.83 11.77 15.37 
Length of hospital stay 
Dbar 5.667 152 — 
DIC 7.677 175.7 — 
pD 2.011 23.75 — 
Dbar: posterior mean of deviance; DIC: deviance information criteria; pD: effective number of parameters or leverage.
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– 0.95 (0.04 to 28.25) 0.70 (0.35 to 1.39) 0.44 (0.05 to 3.67) 0.27 (0.03 to 
1.33) 
– – 
Rifaximin 0.57 (0.33 to 1.00) – 1.72 (0.07 to 40.77) – – 0.76 (0.25 to 
2.21) 
– 
Norfloxacin 0.74 (0.49 to 1.09) 1.29 (0.75 to 2.12) – 1.37 (0.55 to 3.54) 0.70 (0.02 to 
22.74) 
0.50 (0.17 to 
1.38) 
1.82 (0.43 to 
10.40) 
Ciprofloxacin 0.61 (0.31 to 1.16) 1.08 (0.46 to 2.33) 0.83 (0.42 to 1.63) – – – – 
Sulfamethoxazole + 
trimethoprim 
0.47 (0.20 to 1.00) 0.81 (0.33 to 1.88) 0.63 (0.29 to 1.27) 0.76 (0.29 to 2.00) – – – 
Norfloxacin + rifax­
imin 
0.40 (0.12 to 1.17) 0.69 (0.22 to 1.93) 0.54 (0.17 to 1.51) 0.64 (0.18 to 2.16) 0.85 (0.22 to 
3.04) 
– – 
Rufloxacin 1.45 (0.27 to 8.21) 2.52 (0.47 to 15.55) 1.93 (0.39 to 10.36) 2.34 (0.41 to 
13.93) 
3.11 (0.53 to 
19.09) 





verse events (odds 
ratio (95% credible 
interval)) 
No active intervention Rifaximin Norfloxacin — — — — 
No active interven­
tion 
– 0.96 (0.04 to 23.29) – — — — — 
Rifaximin 1.01 (0.00 to 853.21) – 12.35 (0.15 to 
10678.63) 
— — — — 
Norfloxacin 11.85 (0.01 to 263,023.85) 12.60 (0.15 to 
11707.68) 
– — — — — 
Liver transplanta­
tion (hazard ratio 
No active intervention Norfloxacin Ciprofloxacin Sulfamethoxa­
zole + trimetho­
prim 































































































































































































                 
           




             
               
                 
                 
                       
             
                                                     
                                               
                                                       
                                                           
                                                             
                                                     
                                                                   
                   



















– 0.91 (0.29 to 3.01) – – — — — 
Norfloxacin 0.93 (0.31 to 3.44) – 0.66 (0.19 to 2.12) 2.71 (1.10 to 7.59) — — — 
Ciprofloxacin 0.62 (0.12 to 3.31) 0.67 (0.19 to 2.12) – – — — — 
Sulfamethoxazole + 
trimethoprim 
2.62 (0.62 to 11.91) 2.74 (1.12 to 7.08) 4.08 (0.92 to 19.61) – — — — 
Number of decom­
pensation episodes 
(rate ratio (95% 
credible interval)) 







– 0.63 (0.48 to 0.82) 0.78 (0.54 to 1.09) – 0.05 (0.00 to 
0.35) 
— — 
Rifaximin 0.61 (0.46 to 0.80) – 3.60 (0.75 to 27.30) 1.01 (0.10 to 
10.94) 
– — — 
Norfloxacin 0.81 (0.58 to 1.12) 1.34 (0.89 to 2.01) – 0.29 (0.03 to 1.36) – — — 
Norfloxacin + rifax­
imin 
0.33 (0.04 to 1.40) 0.54 (0.07 to 2.29) 0.40 (0.05 to 1.73) – – — — 
Norfloxacin + 
neomycin 

































































































































































The table provides the effect estimates of each pairwise comparison for the different outcomes. The top half of the subtable for each outcome indicates the effect estimates from
 
the direct comparisons. The bottom half of the subtable for each outcome indicates the effect estimates from the network meta­analysis. For network meta­analysis, to identify
 
the effect estimate of a comparison, for example A versus B, look at the cell that occupies the row corresponding to intervention A and the column corresponding to intervention
 
B for the direct effect estimate. If that cell is empty (indicated by '–'), look at the row corresponding to intervention B and the column corresponding to intervention A. Take the
 
inverse of this number (i.e. 1/number) to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column
 
corresponding to intervention A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty, look at the column corresponding to intervention
 
B and the row corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus B. If the cell corresponding to B versus A is also missing
 
in direct comparisons, this means that there was no direct comparison.
 
Italics indicate statistically significant results
 















             
     
             
         
     
       
     
         
 
                             










Appendix 1. Search strategies
 





Issue 11, 2018 #1 MeSH descriptor: [Antibiotic Prophylaxis] explode all trees 
#2 antibiotic* 
#3 antibacteri* near prophyl* 
#4 #1 or #2 or #3 




MEDLINE Ovid January 1947 to 
November 2018 

















18. exp animals/ not humans.sh. 
19. 17 not 18 
20. 8 and 19 
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January 1945 to 
November 2018 
#1 TS=(antibiotic*) 
#2 TS=(antibacteri* near prophyl*) 
#3 #2 OR #1 
#4 TS=((hepatic or liver) and (fibrosis or cirrhosis or cirrhotic)) 
#5 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta­





















This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3601730.
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Conceiving the protocol: KG
 
Designing the protocol: KG
 
Co­ordinating the protocol: KG
 
Designing search strategies: KG
 
Writing the protocol: KG
 
Providing general advice on the protocol: ET, PW
 
Securing funding for the protocol: KG
 




Co­ordinating the review: KG
 
Study selection: KG, LP, AB, MP, DR
 
Data extraction: KG, LP
 
Writing the review: KG, DR
 
Providing advice on the review: PW, SF, AJS, NH, EJM, MC, DT, CSP, BRD, ET
 




































•	 University College London, UK.
 




•	 National Institute for Health Research, UK.
 
Payment for writing reviews, writing equipment, software
 
D I F F E R E N C E S  B E T W E E N  P R O T O C O L  A N D  R E V I E W
 
We made some changes from our published protocol (Gurusamy 2018).

•	 We did not perform Trial Sequential Analysis because the risk of false positive results with Bayesian meta­analysis is probably less or
 
at least equivalent to Trial Sequential Analysis.
 
•	 We used the latest guidance from the GRADE Working group (Yepes­Nunez 2019) rather than the previous guidance (Puhan 2014) for
 
presenting the 'Summary of findings' tables.
 
•	 The trials did not report the proportion of people with other episodes of decompensation but reported the number of episodes of
 
decompensation. Therefore, we treated this as a count outcome and used the Poisson likelihood to calculate the rate ratio.
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•	 In the absence of a protocol published prior to the start of the study, we classified the risk of bias as low for selective reporting bias
 
only when reporting mortality, adverse events, and spontaneous bacterial peritonitis, as we anticipated these outcomes to be routinely
 
measured in clinical trials of this nature.
 
•	 We used 30,000 iterations (instead of 10,000 iterations) as a minimum for burn­in of the simulation sampler used to estimate quantities
 
in the statistical models to ensure convergence of the simulation sampler.
 
•	 We did not present some information such as ranking probability tables, rankograms, and surface area under the curve (SUCRA plots)
 
because of the concern about the misinterpretation of the results. We have highlighted this clearly within the text of the review along
 




The 'Methods' section of this review was based on a standard Cochrane Hepato­Biliary Group template, incorporating advice by the
 
Complex Reviews Support Unit for a network meta­analysis review (Best 2018).
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